

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:53:44 ON 09 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Mar 2005 VOL 142 ISS 11
FILE LAST UPDATED: 8 Mar 2005 (20050308/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 12:52:20 ON 09 MAR 2005)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:52:25 ON 09 MAR 2005
E LACTOFERRIN

L1 224 S E3,E4,E8
L2 23 S E1,E2,E5-E7 NOT L1

FILE 'HCAPLUS' ENTERED AT 12:53:57 ON 09 MAR 2005
E LACTOFERRIN/CT

L3 3804 S E6-E10
E E6+ALL
L4 3828 S E4,E3
L5 4954 S LACTOFERRIN OR LACTOTRANSFERRIN
L6 349 S L1 OR L2
L7 5056 S L3-L6
L8 1 S LACTO() (FERRIN OR TRANSFERRIN OR TRANS FERRIN)
L9 5056 S L7,L8
E ATHEROSCLEROSIS/CT
L10 26376 S E3,E4
E E3+ALL
L11 5033 S E10-E13
L12 45035 S E9,E11,E12,E13/BI
E E8+ALL
L13 8095 S E8
L14 10796 S E8/BI
E E15+ALL
L15 8237 S E4
L16 32 S L9 AND L10-L15
E CARDIOVASCULAR/CT
E E5+ALL
L17 63843 S E3+NT
E E19+ALL
L18 245711 S E4,E3+NT
E E250+ALL
L19 375833 S E3+NT

E HEART DISEASE/CT
 E E4+ALL
 E E2+ALL
 L20 82991 S E8,E9,E7+NT
 E E92+ALL
 L21 216429 S E5,E4+NT
 L22 6523 S E10+OLD,NT
 L23 189 S L9 AND L17-L22
 L24 12 S L9 AND CARDIOVASCULAR(L) (DISEASE OR DISORDER OR DYSFUNCTION?)
 L25 194 S L16,L23,L24

FILE 'REGISTRY' ENTERED AT 12:59:21 ON 09 MAR 2005
 L26 1 S CHOLESTEROL/CN
 E C-REACTIVE PROTEIN/CN
 L27 1 S E3
 L28 106 S C REACTIVE PROTEIN

FILE 'HCAPLUS' ENTERED AT 13:00:01 ON 09 MAR 2005
 L29 107734 S L26 OR L27 OR L28
 L30 60 S L29 AND L9
 L31 137 S (?CHOLESTER? OR CRP OR C REACTIVE(L) PROTEIN) AND L9
 L32 30 S TRIGLYCER? AND L9
 L33 33 S ?VASCUL? (L) ?INFLAM? AND L9
 L34 1 S ?VASCUL? (L) ?SPASM? AND L9
 L35 1 S BLOOD VESSEL+OLD,NT/CT (L) SPASM? AND L9
 L36 1 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) SPASM? AND L9
 L37 34 S PROTEIN?/CW,CT (L) C REACTIVE AND L9
 L38 1 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) HYPERREACT? AND L9
 L39 1 S BLOOD VESSEL+OLD,NT/CT (L) HYPERREACT? AND L9
 L40 6 S BLOOD VESSEL+OLD,NT/CT (L) SMOOTH MUSCL? AND L9
 L41 4 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) SMOOTH MUSCL? AND L9
 L42 6 S INFLAMM?/CW,CT (L) VASCUL? AND L9
 L43 0 S INFLAMM?/CW,CT (L) PRO(L)CYTOKIN? AND L9
 L44 10 S INFLAMM?/CW,CT (L) CYTOKIN? AND L9
 L45 37 S CYTOKINE?/CW,CT (L) ?INFLAM? AND L9
 E CYTOKINE/CT
 L46 72 S E77+OLD,NT (L) ?INFLAM? AND L9
 L47 14 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) ENDOTHEL? AND L9
 L48 39 S BLOOD VESSEL+OLD,NT/CT (L) ENDOTHEL? AND L9
 L49 12 S ENDOTHELIUM+OLD,NT/CT (L) VASCUL? AND L9
 E HYPERCHOLESTEROL/CT
 L50 7 S E5,E6 AND L9
 E E5+ALL
 L51 0 S E5 AND L9
 E HYPERTRIGLYCER/CT
 E E4+ALL
 L52 4 S E4,E5 AND L9
 E LOW DENSITY LIPOPROTEIN/CT
 E L DENSITY LIPOPROTEIN/CT
 E LIPOPROTEIN/CT
 L53 12 S E100-E109,E113,E114 AND L9
 L54 54 S E135-E146 AND L9
 E E51+ALL
 L55 56 S E2+NT (L) (LOW OR VERY LOW) () (DENSITY OR D OR DEN) AND L9
 L56 12 S E2+NT (L) HIGH() (DENSITY OR D OR DEN) AND L9
 L57 19 S E2+NT (L) (LDL OR VLDL OR HDL OR VHDL) AND L9
 L58 401 S L30-L57,L25
 L59 1 S US20040152623/PN OR WO2003-US38540/AP,PRN
 E VARADHACHARY A/AU
 L60 19 S E3,E7
 E GLYNN P/AU
 L61 53 S E3-E9,E17-E19
 E WANG Y/AU

L62 2479 S E3,E40-E43
 E WANG YEN/AU
 L63 11 S E3,E34
 L64 13 S E50
 E ENGELMAYER J/AU
 L65 9 S E4
 E AGENNIX/AP,CS
 E AGENNIX/PA,CS
 E AGENIX/PA,CS
 L66 17 S E3-E21
 L67 10 S L59-L66 AND L58
 L68 10 S L67 AND L3-L25,L29-L67
 L69 341 S L58 AND (PD<=20021204 OR PRD<=20021204 OR AD<=20021204)
 L70 106 S L69 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
 E DRUG DELIVERY/CT
 L71 2 S E27-E31,E39 AND L70
 L72 0 S E53,E55,E58,E64,E70,E71 AND L70
 L73 0 S E89,E107 AND L70
 L74 50 S E6-E217 AND L70
 E E6+ALL
 L75 6 S E3-E5 AND L70
 L76 53 S E2+NT AND L70
 L77 53 S L71,L74-L76
 L78 106 S L70,L77

FILE 'REGISTRY' ENTERED AT 13:36:48 ON 09 MAR 2005

FILE 'REGISTRY' ENTERED AT 13:37:26 ON 09 MAR 2005

L79 14 S 59-67-6 OR 943-45-3 OR 11041-12-6 OR 50925-79-6 OR 182815-43-
 L80 717 S (59-67-6 OR 943-45-3 OR 11041-12-6 OR 50925-79-6 OR 182815-43
 L81 1 S 9028-35-7

FILE 'HCAPLUS' ENTERED AT 13:38:11 ON 09 MAR 2005

L82 6 S L79,L80,L81 AND L78
 L83 8 S L79,L80,L81 AND L69
 L84 1 S BILE ACID (L) SEQUESTR? AND L69,L78
 L85 7 S L82-L84,L78 AND ?ATHEROSCLERO?
 L86 23 S L69 AND ?ATHEROSCLERO?
 L87 23 S L85,L86
 SEL DN AN 1 7 12
 L88 3 S L87 AND E1-E7
 L89 99 S L78 NOT L87
 SEL DN AN 8 19 21 68 89
 DEL SEL
 SEL DN AN 8 19 21 68 96
 L90 5 S L89 AND E1-E15
 L91 16 S L88,L90,L68
 L92 16 S L91 AND L3-L25,L29-L78,L82-L91

FILE 'HCAPLUS' ENTERED AT 13:53:44 ON 09 MAR 2005

=> d all hitstr tot 192

L92 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:77958 HCAPLUS
 DN 142:175360
 ED Entered STN: 28 Jan 2005
 TI Lactoferrin as an adjuvant in cancer vaccines
 IN Varadhachary, Atul; Pericle, Federica
 PA Agennix Incorporated, USA
 SO U.S. Pat. Appl. Publ., 22 pp., which
 CODEN: USXXCO
 DT Patent

LA English
 IC ICM A61K039-00
 ICS A61K038-40
 NCL 424185100; 514006000
 CC 15-2 (Immunochemistry)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005019342	A1	20050127	US 2004-862213	20040607
PRAI	US 2003-476318P	P	20030606		
	US 2003-498236P	P	20030827		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 2005019342	ICM	A61K039-00
	ICS	A61K038-40
	NCL	424185100; 514006000

AB The present invention relates to methods of treating cancer by administering a composition of lactoferrin (LF) in combination with cancer vaccines. The examples describe the oral LF inhibition of Her-2/Neu+ transplantable carcinoma (TUBO) in mouse model; evaluation of recombinant human (rh) LF as adjuvant of p185 DNA vaccine in the prevention and treatment of TUBO in mice; oral LF in inhibition of spontaneous carcinomas; oral LF and DNA vaccination in inhibition of spontaneous carcinomas; oral LF in combination with tumor cell vaccination in inhibition of spontaneous carcinomas; and oral administration of hLF in combination with a cancer vaccine in patients.

ST lactoferrin adjuvant cancer vaccine

IT Leukemia
 (acute lymphocytic; lactoferrin as adjuvant in cancer vaccines)

IT Leukemia
 (acute myelogenous; lactoferrin as adjuvant in cancer vaccines)

IT Immunostimulants
 (adjuvants; lactoferrin as adjuvant in cancer vaccines)

IT Neuroglia, neoplasm
 (astrocytoma; lactoferrin as adjuvant in cancer vaccines)

IT Therapy
 (biotherapy; lactoferrin as adjuvant in cancer vaccines in combination with)

IT Bos taurus
 (bovine or human lactoferrin as adjuvant in cancer vaccines)

IT Drug delivery systems
 (carriers; lactoferrin as adjuvant in cancer vaccines)

IT Uterus, neoplasm
 (cervix; lactoferrin as adjuvant in cancer vaccines)

IT Leukemia
 (chronic lymphocytic; lactoferrin as adjuvant in cancer vaccines)

IT Leukemia
 (chronic myelocytic; lactoferrin as adjuvant in cancer vaccines)

IT Leukemia
 (chronic myelomonocytic leukemia; lactoferrin as adjuvant in cancer vaccines)

IT Intestine, neoplasm
 (colon; lactoferrin as adjuvant in cancer vaccines)

IT Neuroglia, neoplasm
 (glioblastoma; lactoferrin as adjuvant in cancer vaccines)

IT Mouth, neoplasm
 (gum; lactoferrin as adjuvant in cancer vaccines)

IT Neoplasm

(hematol.; **lactoferrin** as adjuvant in cancer vaccines)

IT Cytokines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunomodulatory; **lactoferrin** as adjuvant in cancer vaccines containing)

IT Antitumor agents
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Combination chemotherapy
Digestive tract, neoplasm
Genetic vectors
Head, neoplasm
Human
Immunotherapy
Kidney, neoplasm
Leukemia
Lymphoma
Mammary gland, neoplasm
Melanoma
Multiple myeloma
Myelodysplastic syndromes
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Sarcoma
Testis, neoplasm
Tongue, neoplasm
(**lactoferrin** as adjuvant in cancer vaccines)

IT **Lactoferrins**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**lactoferrin** as adjuvant in cancer vaccines)

IT Nucleic acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**lactoferrin** as adjuvant in cancer vaccines containing)

IT Chemotherapy
Radiotherapy
Surgery
(**lactoferrin** as adjuvant in cancer vaccines in combination with)

IT Antigen-presenting cell
CD4-positive T cell
CD8-positive T cell
Dendritic cell
Hematopoietic precursor cell
T cell (lymphocyte)
(**lactoferrin** as adjuvant in cancer vaccines in relation to activation of)

IT Interleukin 18
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**lactoferrin** as adjuvant in cancer vaccines in relation to formation of)

IT neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**lactoferrin** as vaccine adjuvant in Neu-expressing cancers)

IT Chemokines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(macrophage inflammatory protein 3 α ;

lactoferrin as adjuvant in cancer vaccines in relation to formation of)

IT Mesothelium, neoplasm
(mesothelioma; **lactoferrin** as adjuvant in cancer vaccines)

IT Lymphocyte
(natural killer cell; **lactoferrin** as adjuvant in cancer vaccines in relation to activation of)

IT Neoplasm
(neck; **lactoferrin** as adjuvant in cancer vaccines)

IT Astrocyte
(neoplasm, astrocytoma; **lactoferrin** as adjuvant in cancer vaccines)

IT Neck, anatomical
(neoplasm; **lactoferrin** as adjuvant in cancer vaccines)

IT Nerve, neoplasm
(neuroblastoma; **lactoferrin** as adjuvant in cancer vaccines)

IT Lung, neoplasm
(non-small-cell carcinoma; **lactoferrin** as adjuvant in cancer vaccines)

IT Drug delivery systems
(oral; **lactoferrin** as adjuvant in cancer vaccines)

IT Antigens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p185; **lactoferrin** as adjuvant in cancer vaccines containing DNA encoding)

IT Drug delivery systems
(parenterals; **lactoferrin** as adjuvant in cancer vaccines)

IT Carcinoma
(pulmonary non-small-cell; **lactoferrin** as adjuvant in cancer vaccines)

IT Carcinoma
(pulmonary small-cell; **lactoferrin** as adjuvant in cancer vaccines)

IT Eye, neoplasm
(retinoblastoma; **lactoferrin** as adjuvant in cancer vaccines)

IT Lung, neoplasm
(small-cell carcinoma; **lactoferrin** as adjuvant in cancer vaccines)

IT Carcinoma
(squamous cell; **lactoferrin** as adjuvant in cancer vaccines)

IT Drug delivery systems
(topical; **lactoferrin** as adjuvant in cancer vaccines)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tumor-associated; **lactoferrin** as adjuvant in DNA cancer vaccines promoting recognition of)

IT Vaccines
(tumor; **lactoferrin** as adjuvant in cancer vaccines)

IT DNA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine; **lactoferrin** as adjuvant in cancer vaccines containing)

IT Antitumor agents
(vaccines; **lactoferrin** as adjuvant in cancer vaccines)

IT 56-40-6, Glycine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-terminal glycine absence in **lactoferrin** variant)

IT 83869-56-1, Granulocyte-macrophage colony-stimulating factor
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**lactoferrin** as adjuvant in cancer vaccines in relation to formation of)

IT 832811-61-7 832811-62-8 832811-63-9 832811-64-0
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; **lactoferrin** as an adjuvant in
 cancer vaccines)
 IT 151812-50-9 154427-28-8 160212-35-1 163816-02-2 204380-35-8
 473461-56-2
 RL: PRP (Properties)
 (unclaimed sequence; **lactoferrin** as an adjuvant in cancer
 vaccines)

L92 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:1033558 HCAPLUS
 DN 141:420455
 ED Entered STN: 02 Dec 2004
 TI Compositions comprising recombinant **lactoferrin** and its variants
 in the treatment of diabetes mellitus
 IN Engelmayr, Jose; Varadachary, Atul
 PA Agennix Incorporated, USA
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 1-10 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103285	A2	20041202	WO 2004-US14985	20040513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005004006	A1	20050106	US 2004-844865	20040513
PRAI	US 2003-470549P	P	20030514		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004103285	ICM	A61K

AB The present invention relates to methods of using a composition of **lactoferrin** for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated Hb (HbA1c).
 ST human recombinant **lactoferrin** variant antidiabetic hyperglycemia; recombinant **lactoferrin** antiobesity antihypertensive
 IT Drug delivery systems
 (carriers; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)
 IT Antidiabetic agents
Antihypertensives
 Antiobesity agents
 Chelating agents
 Diabetes mellitus
 Hyperglycemia
 Hypertension
 Obesity

(compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Lactoferrins**
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Hemoglobins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glycohemoglobins; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Drug delivery systems**
(injections, i.m.; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Drug delivery systems**
(injections, i.v.; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Drug delivery systems**
(injections, s.c.; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Diabetes mellitus**
(insulin-dependent; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Body weight**
(**lactoferrin** composition reducing; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Bos taurus**
Human
Mammalia
(**lactoferrin**; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Intestine**
(large, **lactoferrin** releasing in; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Diabetes mellitus**
(non-insulin-dependent; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Drug delivery systems**
(oral; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Drug delivery systems**
(parenterals; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Intestine**
(small, **lactoferrin** releasing in; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT **Drug delivery systems**
(transdermal; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT 60-00-4, EDTA, biological studies 67-42-5, EGTA 150-39-0, HEDTA
85233-19-8, BAPTA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as metal chelator; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blood; compns. comprising recombinant **lactoferrin** and its variants in treatment of diabetes mellitus)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increased level of; compns. comprising recombinant **lactoferrin**)

and its variants in treatment of diabetes mellitus)

L92 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:531382 HCAPLUS
 DN 141:47367
 ED Entered STN: 02 Jul 2004
 TI Lactoferrin for the reduction of pain
 IN Varadhachary, Atul; Petrak, Karel
 PA Agennix Incorporated, USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K038-40

ICS C07K014-00

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054608	A2	20040701	WO 2003-US39358	20031211
	WO 2004054608	A3	20040805		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004151784	A1	20040805	US 2003-733621	20031211
PRAI	US 2002-432937P	P	20021212		
	US 2003-498248P	P	20030827		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004054608	ICM	A61K038-40
	ICS	C07K014-00
US 2004151784	ECLA	A61K038/40; A61K038/40+M

AB The invention discloses methods of using lactoferrin to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.

ST lactoferrin pain treatment

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNF- α ; lactoferrin for reduction of pain. and use with other therapeutic means)

IT Pain (acute; lactoferrin for reduction of pain. and use with other therapeutic means)

IT Acupuncture (and acupressure; lactoferrin for reduction of pain. and use with other therapeutic means)

IT Lactoferrins RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (and variants; lactoferrin for reduction of pain. and use with other therapeutic means)

IT Bos taurus (bovine lactoferrin; lactoferrin for reduction of pain.)

and use with other therapeutic means)

IT Metals, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chelators for; **lactoferrin** for reduction of pain. and use with
other therapeutic means)

IT Therapy
(chiropractic; **lactoferrin** for reduction of pain. and use with
other therapeutic means)

IT Pain
(chronic; **lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Drug delivery systems
(delayed release; **lactoferrin** for reduction of pain. and use with
other therapeutic means)

IT Anesthesia
(general; **lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Anesthetics
(i.v.; **lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Analgesics
Antacids
Antidepressants
Chelating agents
Drug delivery systems
Human
Pain
(**lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Opioids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(**lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Intestine
(large, **lactoferrin** release in; **lactoferrin** for
reduction of pain. and use with other therapeutic means)

IT Anesthesia
(local; **lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Therapy
(non-pharmacol. pain management techniques; **lactoferrin** for
reduction of pain. and use with other therapeutic means)

IT Anti-inflammatory agents
(nonsteroidal; **lactoferrin** for reduction of pain. and use with
other therapeutic means)

IT Drug delivery systems
(opioid pump; **lactoferrin** for reduction of pain. and use with
other therapeutic means)

IT Drug delivery systems
(oral; **lactoferrin** for reduction of pain. and use with other
therapeutic means)

IT Drug delivery systems
(parenterals; **lactoferrin** for reduction of pain. and use with
other therapeutic means)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**proinflammatory**; **lactoferrin** for reduction of pain.
and use with other therapeutic means)

IT Anesthesia
 (regional; **lactoferrin** for reduction of pain. and use with other therapeutic means)

IT Intestine
 (small, **lactoferrin** release in; **lactoferrin** for reduction of pain. and use with other therapeutic means)

IT Anesthesia
 (spinal; **lactoferrin** for reduction of pain. and use with other therapeutic means)

IT Drug delivery systems
 (topical; **lactoferrin** for reduction of pain. and use with other therapeutic means)

IT 56-40-6, Glycine, properties
 RL: PRP (Properties)
 (amino-terminal; **lactoferrin** for reduction of pain. and use with other therapeutic means)

IT 60-00-4, EDTA, biological studies 67-42-5, EGTA
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**lactoferrin** for reduction of pain. and use with other therapeutic means)

L92 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:513498 HCAPLUS

DN 141:47315

ED Entered STN: 25 Jun 2004

TI **Lactoferrin** as an agent in the prevention of organ transplant rejection and graft-versus-host-disease

IN Varadhachary, Atul; Pericle, Federica

PA Agennix Incorporated, USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-7 (Pharmacology)

Section cross-reference(s): 2, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052305	A2	20040624	WO 2003-US39265	20031210
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004176276	A1	20040909	US 2003-732429	20031210
PRAI	US 2002-432113P	P	20021210		
	US 2003-498338P	P	20030827		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004052305	ICM	A61K
---------------	-----	------

AB The present invention relates to methods of using **lactoferrin** (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-vs.-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver,

pancreas and stem cells by administering a composition of **lactoferrin** to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with **lactoferrin** to attenuate the development of graft-vs.-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with **lactoferrin** to attenuate the development of graft rejection in the recipients.

ST **lactoferrin** immunomodulator transplant rejection xenograft

IT CD3 (antigen)

CD4 (antigen)

CD8 (antigen)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (T-lymphocytes expressing; **lactoferrin** as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Drug delivery systems (carriers; **lactoferrin** as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Drug delivery systems (delayed release; **lactoferrin** as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation (graft-vs.-host reaction; **lactoferrin** as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation (heart; **lactoferrin** as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation (kidney; **lactoferrin** as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Bos taurus

Human

Immune tolerance

Immunosuppressants

Molecular cloning

Stem cell

Transplant and Transplantation

Transplant rejection (lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT **Lactoferrins**

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Interleukin 18

RL: BSU (Biological study, unclassified); BIOL (Biological study) (lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Intestine (large, lactoferrin release in; lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation

Transplant and Transplantation (liver; lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation

Transplant and Transplantation (lung; lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

IT **Chemokines**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(macrophage inflammatory protein 3 α ;
lactoferrin as an agent in the prevention of organ transplant
 rejection and graft-vs.-host-disease)

IT Immunity
 (mucosal; **lactoferrin** as an agent in the prevention of organ
 transplant rejection and graft-vs.-host-disease)

IT Lymphocyte
 (natural killer cell, regulation of; **lactoferrin** as an agent
 in the prevention of organ transplant rejection and
 graft-vs.-host-disease)

IT Drug delivery systems
 (oral; **lactoferrin** as an agent in the prevention of organ
 transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation
 (pancreas; **lactoferrin** as an agent in the prevention of organ
 transplant rejection and graft-vs.-host-disease)

IT Drug delivery systems
 (parenterals; **lactoferrin** as an agent in the prevention of
 organ transplant rejection and graft-vs.-host-disease)

IT Cytokines
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (proinflammatory; **lactoferrin** as an agent in the
 prevention of organ transplant rejection and graft-vs.-host-disease)

IT Antigen-presenting cell
 B cell (lymphocyte)
 Macrophage
 Polymorphonuclear leukocyte
 T cell (lymphocyte)
 (regulation of; **lactoferrin** as an agent in the prevention of
 organ transplant rejection and graft-vs.-host-disease)

IT Intestine
 (small, **lactoferrin** release in; **lactoferrin** as an
 agent in the prevention of organ transplant rejection and
 graft-vs.-host-disease)

IT Bone marrow
 (stem cells of; **lactoferrin** as an agent in the prevention of
 organ transplant rejection and graft-vs.-host-disease)

IT Immunity
 (systemic; **lactoferrin** as an agent in the prevention of organ
 transplant rejection and graft-vs.-host-disease)

IT Bone marrow
 (toxicity, stem cells of; **lactoferrin** as an agent in the
 prevention of organ transplant rejection and graft-vs.-host-disease)

IT Heart
 Kidney
 Liver
 Liver
 Lung
 Lung
 Pancreas
 (transplant; **lactoferrin** as an agent in the prevention of
 organ transplant rejection and graft-vs.-host-disease)

IT Transplant and Transplantation
 (xenotransplant; **lactoferrin** as an agent in the prevention of
 organ transplant rejection and graft-vs.-host-disease)

IT 53-03-2, Prednisone 446-86-6, Azathioprine 59865-13-3, Cyclosporine
 104987-11-3, Tacrolimus 128794-94-5, Mycophenolate mofetil
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (**lactoferrin** as an agent in the prevention of organ
 transplant rejection and graft-vs.-host-disease)

IT 60-00-4, Edta, biological studies 67-42-5, Egta
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lactoferrin as an agent in the prevention of organ transplant rejection and graft-vs.-host-disease)

L92 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:513478 HCAPLUS

DN 141:17581

ED Entered STN: 25 Jun 2004

TI Oral lactoferrin for the treatment of sepsis

IN Varadhachary, Atul; Petrak, Karel

PA Agennix Incorporated, USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-5 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052281	A2	20040624	WO 2003-US38621	20031205
	WO 2004052281	A3	20040910		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2004152624	A1	20040805	US 2003-728521	20031205
PRAI	US 2002-431393P	P	20021206		
	US 2003-498327P	P	20030827		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004052281	ICM	A61K

AB The invention relates to methods of treating prophylactically or therapeutically bacteremia, sepsis, septic shock or related conditions such as ARDS by administering orally a composition of **lactoferrin** alone or in combination with standard therapies or metal chelators to prevent or treat the consequences of bacteria-induced systemic inflammatory response syndrome. In particular it is claimed that the therapeutic use of recombinant human **lactoferrin** alone or in combination with metal chelators or other therapeutic interventions decreases the mortality due to bacteremia, sepsis, septic shock or related conditions such as ARDS.

ST **lactoferrin** oral metal chelator bacteremia sepsis septic shock
 ARDS

IT Lung, disease
 (acute injury; oral **lactoferrin** for treatment of sepsis)

IT Injury
 (acute pulmonary; oral **lactoferrin** for treatment of sepsis)

IT Respiratory distress syndrome
 (acute; oral **lactoferrin** for treatment of sepsis)

IT Drug delivery systems
 (capsules, enteric-coated; oral **lactoferrin** for treatment of sepsis)

IT Drug delivery systems
 (carriers; oral **lactoferrin** for treatment of sepsis)

IT Organ, animal, disease

(failure; oral lactoferrin for treatment of sepsis)
IT Drug delivery systems
(infusions, nasogastric; oral lactoferrin for treatment of sepsis)
IT Drug delivery systems
(injections, i.v.; oral lactoferrin for treatment of sepsis)
IT Immunity
(mucosal; oral lactoferrin for treatment of sepsis)
IT Antacids
Anti-inflammatory agents
Antibiotics
Bacteremia
Blood
Blood plasma
Chelating agents
Death
Digestive tract
Drug interactions
Escherichia coli
Eubacteria
Haemophilus
Human
Immune system
Immunomodulators
Kidney
Liver
Lung
Mucous membrane
Pseudomonas
Sepsis
Spleen
Staphylococcus
Surfactants
(oral lactoferrin for treatment of sepsis)
IT Interleukin 1
Interleukin 10
Interleukin 18
Interleukin 2
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oral lactoferrin for treatment of sepsis)
IT Lactoferrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(oral lactoferrin for treatment of sepsis)
IT Drug delivery systems
(oral; oral lactoferrin for treatment of sepsis)
IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pro-inflammatory; oral lactoferrin for treatment
of sepsis)
IT Shock (circulatory collapse)
(septic; oral lactoferrin for treatment of sepsis)
IT Kidney
Liver
Lung
(toxicity; oral lactoferrin for treatment of sepsis)
IT Medical goods
(tubes, nasogastric; oral lactoferrin for treatment of
sepsis)

IT 60-00-4, Ethylenediaminetetraacetic acid, biological studies 67-42-5,
 Ethylenebis(oxyethylenenitrilo)tetraacetic acid 98530-76-8, Xigris
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (oral lactoferrin for treatment of sepsis)

L92 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:490705 HCAPLUS

DN 141:33800

ED Entered STN: 17 Jun 2004

TI Lactoferrin in the reduction of circulating cholesterol
 , vascular inflammation, atherosclerosis and
 cardiovascular disease

IN Varadhachary, Atul; Glynn, Peter; Wang, Yenyun
 ; Engelmayer, Jose

PA Agennix Incorporated, USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-8 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050037	A2	20040617	WO 2003-US38540	20031204 <--
	WO 2004050037	A3	20040812		
				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	US 2004152623	A1	20040805	US 2003-728275	20031204 <--
PRAI	US 2002-430867P	P	20021204	<--	
	US 2003-498337P	P	20030827		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004050037	ICM A61K	

AB The invention discloses methods for using lactoferrin to reduce
 circulating levels of cholesterol and vascular
 inflammation in order to treat, prevent or reduce the incidence of
 atherosclerosis and cardiovascular disease.

ST lactoferrin hypocholesterolemic vascular
 inflammation atherosclerosis cardiovascular
 disease

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (C-reactive; lactoferrin for reduction of
 cholesterol and vascular inflammation and
 treatment of atherosclerosis and cardiovascular
 disease)

IT Antiarteriosclerotics

(antiatherosclerotics; lactoferrin for reduction of
 cholesterol and vascular inflammation and
 treatment of atherosclerosis and cardiovascular
 disease)

IT Sequestering agents

(bile acid; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease, and use with other agents)

IT Bos taurus
(bovine lactoferrin; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(delayed release; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Blood vessel
(endothelium; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high-d.; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Blood vessel
(hyperreactivity; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(injections, i.m.; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(injections, i.p.; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(injections, i.v.; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(injections, s.c.; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(intraarterial; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(intramyocardial; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(intrathecal; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Anti-inflammatory agents
Anticholesteremic agents
Atherosclerosis
Cardiovascular agents
Cardiovascular system, disease
Drug delivery systems
Human
Hypercholesterolemia
Hypertriglyceridemia
Hypolipemic agents
(lactoferrin for reduction of cholesterol and
vascular inflammation and treatment of
atherosclerosis and cardiovascular disease)
IT Lactoferrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(lactoferrin for reduction of cholesterol and
vascular inflammation and treatment of
atherosclerosis and cardiovascular disease)
IT Antacids
(lactoferrin for reduction of cholesterol and
vascular inflammation and treatment of
atherosclerosis and cardiovascular disease,
and use with other agents)
IT Intestine
(large, lactoferrin release in; lactoferrin for
reduction of cholesterol and vascular
inflammation and treatment of atherosclerosis and
cardiovascular disease)
IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(low-d.; lactoferrin for reduction of
cholesterol and vascular inflammation and
treatment of atherosclerosis and cardiovascular
disease)
IT Drug delivery systems
(oral; lactoferrin for reduction of cholesterol
and vascular inflammation and treatment of
atherosclerosis and cardiovascular disease)
IT Drug delivery systems
(parenterals; lactoferrin for reduction of
cholesterol and vascular inflammation and
treatment of atherosclerosis and cardiovascular
disease)
IT Immunosuppressants
(pro-inflammatory cytokine reduction; lactoferrin for
reduction of cholesterol and vascular
inflammation and treatment of atherosclerosis and
cardiovascular disease)
IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proinflammatory; lactoferrin for reduction of
cholesterol and vascular inflammation and
treatment of atherosclerosis and cardiovascular
disease)
IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequestrants; lactoferrin for reduction of
cholesterol and vascular inflammation and
treatment of atherosclerosis and cardiovascular
disease, and use with other agents)
IT Intestine
(small, lactoferrin release in; lactoferrin for

reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Blood vessel
(smooth muscle; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Blood vessel, disease
(spasm; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug interactions
(synergistic; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease, and use with other agents)

IT Drug delivery systems
(transendocardial; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Drug delivery systems
(transepocardial; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Biological transport
(uptake, cholesterol absorption inhibitors; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease, and use with other agents)

IT Cell proliferation
Cytotoxic agents
(vascular smooth muscle cell; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Endothelium
(vascular; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Blood vessel, disease
Inflammation
(vasculitis; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(very-low-d.; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease)

IT 9028-35-7, HMG-CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; lactoferrin for reduction of cholesterol and vascular inflammation and treatment of atherosclerosis and cardiovascular disease, and use with other agents)

IT 57-88-5, Cholesterol, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lactoferrin for reduction of cholesterol and
 vascular inflammation and treatment of
 atherosclerosis and cardiovascular disease)

IT 59-67-6, Nicotinic acid, biological studies 637-07-0,
 Clofibrate 943-45-3D, Fibric acid, derivs. 11041-12-6,
 Cholestyramine 25812-30-0, Gemfibrozil 49562-28-9,
 Fenofibrate 50925-79-6, Cholestipol 75330-75-5,
 Lovastatin 79902-63-9, Simvastatin 81093-37-0,
 Pravastatin 93957-54-1, Fluvastatin 134523-00-5,
 Atorvastatin 145599-86-6, Cerivastatin 182815-43-6,
 Colesevelam
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (lactoferrin for reduction of cholesterol and
 vascular inflammation and treatment of
 atherosclerosis and cardiovascular disease,
 and use with other agents)

IT 9028-35-7, HMG-CoA reductase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; lactoferrin for reduction of cholesterol
 and vascular inflammation and treatment of
 atherosclerosis and cardiovascular disease,
 and use with other agents)


RN 9028-35-7 HCAPLUS
 CN Reductase, hydroxymethylglutaryl coenzyme A (reduced nicotinamide adenine
 dinucleotide phosphate) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 57-88-5, Cholesterol, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lactoferrin for reduction of cholesterol and
 vascular inflammation and treatment of
 atherosclerosis and cardiovascular disease)

RN 57-88-5 HCAPLUS
 CN Cholest-5-en-3-ol (3 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 59-67-6, Nicotinic acid, biological studies 637-07-0,
 Clofibrate 943-45-3D, Fibric acid, derivs. 11041-12-6,
 Cholestyramine 25812-30-0, Gemfibrozil 49562-28-9,
 Fenofibrate 50925-79-6, Cholestipol 75330-75-5,
 Lovastatin 79902-63-9, Simvastatin 81093-37-0,
 Pravastatin 93957-54-1, Fluvastatin 134523-00-5,
 Atorvastatin 145599-86-6, Cerivastatin 182815-43-6,
 Colesevelam
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(lactoferrin for reduction of cholesterol and
vascular inflammation and treatment of
atherosclerosis and cardiovascular disease,
and use with other agents)


RN 59-67-6 HCPLUS

CN 3-Pyridinecarboxylic acid (9CI) (CA INDEX NAME)




RN 637-07-0 HCPLUS

CN Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 943-45-3 HCPLUS

CN Propanoic acid, 2-methyl-2-phenoxy- (9CI) (CA INDEX NAME)




RN 11041-12-6 HCPLUS

CN Cholestyramine (7CI, 8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 25812-30-0 HCPLUS

CN Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 49562-28-9 HCPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 50925-79-6 HCAPLUS
 CN Colestipol (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 75330-75-5 HCAPLUS
 CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 79902-63-9 HCAPLUS
 CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81093-37-0 HCAPLUS
 CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,

(βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 93957-54-1 HCPLUS

CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 134523-00-5 HCPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145599-86-6 HCPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



RN 182815-43-6 HCAPLUS

CN 1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, chloride, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine (9CI) (CA INDEX NAME)

CM 1

CRN 182815-42-5


CMF C12 H27 N2 . Cl

● Cl⁻

CM 2

CRN 92162-19-1


CMF C13 H27 N



CM 3

CRN 107-11-9


CMF C3 H7 N



CM 4

CRN 106-89-8

CMF C3 H5 Cl O



L92 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:252366 HCAPLUS
 DN 140:276199
 ED Entered STN: 26 Mar 2004
 TI Lactoferrin compositions and methods of wound treatment
 IN Engelmayr, Jose; Varadachary, Atul
 PA Agennix Incorporated, USA
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-40
 ICS C07K014-79
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024180	A1	20040325	WO 2003-US29069	20030916 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004142037	A1	20040722	US 2003-663258	20030916 <--
PRAI	US 2002-410981P	P	20020916		<--

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2004024180	ICM	A61K038-40
		ICS	C07K014-79
	US 2004142037	ECLA	A61K038/40; A61K038/40+M; C07K014/79

AB The present invention relates to lactoferrin compns. and methods of using the compns. to treat wounds. The compns. can be administered alone or in combination with other standard wound healing therapies. Lactoferrin enhances the local immune system and kills bacteria infecting the wound. For example, a recombinant human lactoferrin (rhLF) gel formulation containing 0.1% to 8.5% rhLF comprised phosphate buffer with rhLF 86.67%, Carbopol 980 1.0%, disodium edetate 0.1%, phenoxyethanol 1.0%, glycerin 4.0%, propylene glycol 5.0%, dimethicone 0.4%, citric acid 0.0956%, 20% NaOH as needed to pH 6.5-7.5, and water to 100%. RhLF gels ranging from 0.1% to 8.5% mediated an improvement in the incidence of 75% wound closure of 77% in normal mice at day 12 (p<0.01) and of 66% in diabetic db/db mice at day 15 (p<0.05).

ST lactoferrin oral topical parenteral wound healing

IT Injury

(bone; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT Medical goods

(dressings; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT Glycosaminoglycans, biological studies

Polysaccharides, biological studies

Proteins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gel containing; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Drug delivery systems**
 (gels; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Wound**
 (infection; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Bone, disease**
 (injury; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Antibacterial agents**

Burn

Drug bioavailability

Human

Immunostimulants

Ulcer

Wound

Wound healing promoters
 (oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Chemokines**

Cytokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Lactoferrins**

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Drug delivery systems**
 (oral; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Drug delivery systems**
 (parenterals; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Drug delivery systems**
 (topical; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Diabetes mellitus**
 (ulcer from; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Vein, disease**
 (venous stasis ulcer; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT **Digestive tract**

Infection

Mouth, disease
 (wound; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT 120225-54-9, CGS-21680 165101-51-9, Regranex
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination with; oral, parenteral and topical lactoferrin compns. for wound treatment)

IT 9002-89-5, Polyvinyl alcohol 9003-05-8, Acrylamide polymer 9003-39-8, Polyvinyl pyrrolidone 106392-12-5, Pluronic 138757-67-2, Carbopol 980
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (gel containing; oral, parenteral and topical lactoferrin compns. for wound treatment)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Legrand; Biochem J 1997, V327, P841 HCAPLUS
- (2) Nuijens; US 6333311 B1 2001 HCAPLUS
- (3) Valenti; US 5834424 A 1998 HCAPLUS

(4) van Berkel; Biochemical J 1997, V328, P145 HCAPLUS

L92 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:950872 HCAPLUS
 DN 140:13033
 ED Entered STN: 07 Dec 2003
 TI **Lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases
 IN Varadachary, Atul; Barsky, Rick; Pericle, Frederica; Petrak, Karel; Wang, Yenyun
 PA Agennix Incorporated, USA
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-40
 ICS A23L001-305
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003099323	A1	20031204	WO 2003-US14789	20030509 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004009895	A1	20040115	US 2003-434769	20030509 <--
	US 2004082504	A1	20040429	US 2003-435319	20030509 <--
	EP 1507554	A1	20050223	EP 2003-755357	20030509 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-379441P	P	20020510	<--	
	US 2002-379442P	P	20020510	<--	
	US 2002-379474P	P	20020510	<--	
	WO 2003-US14789	W	20030509		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2003099323	ICM A61K038-40	
		ICS A23L001-305	

AB The present invention relates to methods of treating a hyperproliferative disease by administering a composition of **lactoferrin** alone or in combination with standard anti-cancer therapies.
 ST antitumor **lactoferrin** neoplasm hyperproliferation disease therapy; cancer antitumor human **lactoferrin** hyperproliferation disease therapy
 IT CD3 (antigen)
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (-pos. T cell; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)
 IT Leukemia
 (acute lymphocytic; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)
 IT Leukemia
 (acute myelogenous; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Radiotherapy
(and biotherapy; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Antiarteriosclerotics**
(antiatherosclerotics; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Neuroglia, neoplasm**
(astrocytoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Uterus, neoplasm**
(cervix; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Leukemia**
(chronic lymphocytic; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Leukemia**
(chronic myelomonocytic leukemia; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Intestine, neoplasm**
(colon; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Neoplasm**
(fibroma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Neuroglia, neoplasm**
(glioblastoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Mouth, disease**
(hairy leukoplakia; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Blood vessel, neoplasm**
(hemangioma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Neoplasm**
(hematopoietic; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Carcinoma**
(hepatocellular; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Liver, neoplasm**
(hepatoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Intestine, disease**
(inflammatory; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Drug delivery systems**
(injections, i.v.; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Adenoma**
Antacids
Antiarthritics
Antigen-presenting cell
Antirheumatic agents
Antitumor agents
Atherosclerosis
Bladder, neoplasm
Bone, neoplasm
Bos taurus
Brain, neoplasm
CD4-positive T cell
CD8-positive T cell
Carcinoma

Chemotherapy
Dendrite (neuron)
Digestive tract, neoplasm
Head, neoplasm
Human
Immunostimulants
Immunotherapy
Kidney, neoplasm
Leukemia
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Melanoma
Multiple myeloma
Myelodysplastic syndromes
Neoplasm
Osteoarthritis
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Sarcoma
Surgery
T cell (lymphocyte)
Testis, neoplasm
Tongue, neoplasm
 (lactoferrin in treatment of malignant neoplasms and other
 hyperproliferative diseases)
IT Interleukin 18
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lactoferrin in treatment of malignant neoplasms and other
 hyperproliferative diseases)
IT Lactoferrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (lactoferrin in treatment of malignant neoplasms and other
 hyperproliferative diseases)
IT Myoma
 (leiomyoma; lactoferrin in treatment of malignant neoplasms
 and other hyperproliferative diseases)
IT Adipose tissue, neoplasm
 (lipoma; lactoferrin in treatment of malignant neoplasms and
 other hyperproliferative diseases)
IT Carcinoma
Mesothelium, neoplasm
 (mesothelioma; lactoferrin in treatment of malignant
 neoplasms and other hyperproliferative diseases)
IT Immune system
 (mucosal; lactoferrin in treatment of malignant neoplasms and
 other hyperproliferative diseases)
IT Leukemia
 (myelomonocytic, juvenile; lactoferrin in treatment of
 malignant neoplasms and other hyperproliferative diseases)
IT Lymphocyte
 (natural killer cell; lactoferrin in treatment of malignant
 neoplasms and other hyperproliferative diseases)
IT Neoplasm
 (neck; lactoferrin in treatment of malignant neoplasms and
 other hyperproliferative diseases)
IT Astrocyte
 (neoplasm, astrocytoma; lactoferrin in treatment of malignant
 neoplasms and other hyperproliferative diseases)

IT Gingiva
 Hematopoietic precursor cell
 Neck, anatomical
 (neoplasm; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Nerve, neoplasm
 (neuroblastoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Lung, neoplasm
 (non-small-cell carcinoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Blood vessel, disease
 (occlusion; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Drug delivery systems
 (oral; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Liver, neoplasm
 (preneoplastic nodule; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Carcinoma
 (pulmonary non-small-cell; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Carcinoma
 (pulmonary small-cell; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Artery, disease
 (restenosis; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Eye, neoplasm
 (retinoblastoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Lung, neoplasm
 (small-cell carcinoma; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Carcinoma
 (squamous cell; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT Drug delivery systems
 (topical; **lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT 83869-56-1, Granulocyte-macrophage colony-stimulating factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (**lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

IT 15663-27-1, Cisplatin 114977-28-5, Docetaxel
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**lactoferrin** in treatment of malignant neoplasms and other hyperproliferative diseases)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Kruzel; US 20030096736 A1 2003 HCAPLUS
 (2) Satoh; EP 0730868 A1 1996 HCAPLUS

L92 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:950782 HCAPLUS

DN 140:752

ED Entered STN: 07 Dec 2003

TI Oral **lactoferrin** in the treatment of respiratory disorders

IN Glynn, Peter; Varadhachary, Atul

PA Agennix Incorporated, USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-9 (Pharmacology)

Section cross-reference(s): 2, 14, 15, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003099207	A2	20031204	WO 2003-US15763	20030520 <--
	WO 2003099207	A3	20040408		
		W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004009896	A1	20040115	US 2003-441329	20030520 <--
PRAI	US 2002-383280P	P	20020524	<--	
	US 2002-410645P	P	20020913	<--	

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2003099207 ICM A61K

AB The invention relates to methods of treating an allergic or non-allergic respiratory disorder by administering orally a composition of **lactoferrin** alone or in combination with metal chelators to treat respiratory disorders.

ST **lactoferrin** metal chelator interaction allergic nonallergic respiratory disorder pharmaceutical; surgery **lactoferrin** metal chelator Tcell respiratory disorder asthma antiasthmatic

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (C-reactive, serum; oral **lactoferrin** for treatment of respiratory disorders)

IT Antihistamines (H1; oral **lactoferrin** for treatment of respiratory disorders)

IT Antibodies and Immunoglobulins RL: BSU (Biological study, unclassified); BIOL (Biological study) (IgE, binding inhibitors; oral **lactoferrin** for treatment of respiratory disorders)

IT Drug delivery systems (aerosols, inhalants, hot air; oral **lactoferrin** for treatment of respiratory disorders)

IT Allergy (allergic asthma; oral **lactoferrin** for treatment of respiratory disorders)

IT Allergy Inflammation Nose, disease (allergic rhinitis; oral **lactoferrin** for treatment of respiratory disorders)

IT Asthma (allergic; oral **lactoferrin** for treatment of respiratory disorders)

IT Antibodies and Immunoglobulins RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-CD23; oral **lactoferrin** for treatment of respiratory

disorders)

IT Bronchi, disease
Inflammation
(bronchitis; oral **lactoferrin** for treatment of respiratory disorders)

IT Drug delivery systems
(capsules, enteric-coated; oral **lactoferrin** for treatment of respiratory disorders)

IT Drug delivery systems
(carriers; oral **lactoferrin** for treatment of respiratory disorders)

IT Lung, disease
(chronic obstructive; oral **lactoferrin** for treatment of respiratory disorders)

IT Enzymes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cleaners; oral **lactoferrin** for treatment of respiratory disorders)

IT Mast cell
(degranulation agents; oral **lactoferrin** for treatment of respiratory disorders)

IT Allergy
(delayed hypersensitivity, associated with atopic or non-atopic asthma; oral **lactoferrin** for treatment of respiratory disorders)

IT Antigen-presenting cell
(dendritic; oral **lactoferrin** for treatment of respiratory disorders)

IT Drug delivery systems
(enteric; oral **lactoferrin** for treatment of respiratory disorders)

IT Respiratory tract, disease
(hyperresponsiveness; oral **lactoferrin** for treatment of respiratory disorders)

IT Drug delivery systems
(liqs.; oral **lactoferrin** for treatment of respiratory disorders)

IT Apparatus
(mech. breathing device; oral **lactoferrin** for treatment of respiratory disorders)

IT Atomizing (spraying)
(moisturized by; oral **lactoferrin** for treatment of respiratory disorders)

IT Cosmetics
(moisturizers; oral **lactoferrin** for treatment of respiratory disorders)

IT Drug delivery systems
(nasal sprays, salt-water nasal washes
or; oral **lactoferrin** for treatment of respiratory disorders)

IT Lymphocyte
(natural killer cell; oral **lactoferrin** for treatment of respiratory disorders)

IT Diffusion
(of inflammatory cells into lung; oral **lactoferrin** for treatment of respiratory disorders)

IT Allergy
Antacids
Anti-inflammatory agents
Antiasthmatics
Antibiotics
Antihistamines
Antitussives
Asthma

Blood plasma
Blood serum
Bos taurus
Bronchodilators
CD4-positive T cell
CD8-positive T cell
Chelating agents
Decongestants
Digestive tract
Drug interactions
Emphysema
Eosinophil
Expectorants
Fungicides
Human
Immune system
Immunity
Inflammation
Leukotriene antagonists
Mucous membrane
Respiratory tract, disease
Surgery
T cell (lymphocyte)
 (oral lactoferrin for treatment of respiratory disorders)

IT CD3 (antigen)
 Interleukin 1
 Interleukin 10
 Interleukin 12
 Interleukin 18
 Interleukin 2
 Interleukin 4
 Interleukin 5
 VIP receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (oral lactoferrin for treatment of respiratory disorders)

IT Lactoferrins
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral lactoferrin for treatment of respiratory disorders)

IT Corticosteroids, biological studies
 Glucocorticoids
 Steroids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (oral lactoferrin for treatment of respiratory disorders)

IT Drug delivery systems
 (oral; oral lactoferrin for treatment of
 respiratory disorders)

IT Cytokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pro-inflammatory; oral lactoferrin for treatment
 of respiratory disorders)

IT Inflammation
 Respiratory tract, disease
 (sinusitis, chronic or acute; oral lactoferrin for treatment
 of respiratory disorders)

IT Drug delivery systems
 (solids; oral lactoferrin for treatment
 of respiratory disorders)

IT Drug delivery systems
 (sprays, antihistamine; oral lactoferrin
 for treatment of respiratory disorders)

IT Drug delivery systems

(topical, moisturizing agents; oral lactoferrin for treatment of respiratory disorders)

IT Adrenoceptor antagonists
(α -; oral lactoferrin for treatment of respiratory disorders)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α -; oral lactoferrin for treatment of respiratory disorders)

IT Adrenoceptor antagonists
(β -; oral lactoferrin for treatment of respiratory disorders)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ ; oral lactoferrin for treatment of respiratory disorders)

IT 97501-93-4, Tryptase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; oral lactoferrin for treatment of respiratory disorders)

IT 9041-92-3 10102-43-9, Nitric oxide, biological studies 83869-56-1, GMCSF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oral lactoferrin for treatment of respiratory disorders)

IT 55-92-5, Methacholine 60-00-4, Ethylenediaminetetraacetic acid, biological studies 67-42-5, EGTA 93-14-1, Guaifenesin 150-39-0, HEDTA 7681-11-0, Potassium iodide, biological studies 7782-44-7, Oxygen, biological studies 85233-19-8, BAPTA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral lactoferrin for treatment of respiratory disorders)

L92 ANSWER 10 OF 16 HCPLUS COPYRIGHT 2005 ACS on STN
AN 2003:913030 HCPLUS
DN 139:358755
ED Entered STN: 21 Nov 2003
TI Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
IN Varadhachary, Atul; Petrak, Karel; Barsky, Rick; O'Malley, Bert
PA Agennix Incorporated, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-40
ICS A23L001-305
CC 1-6 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003094952	A1	20031120	WO 2003-US14584	20030509 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004009895	A1	20040115	US 2003-434769	20030509 <--
	US 2004082504	A1	20040429	US 2003-435319	20030509 <--

PRAI US 2002-379441P P 20020510 <--
 US 2002-379442P P 20020510 <--
 US 2002-379474P P 20020510 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003094952	ICM A61K038-40 ICS A23L001-305	
AB	The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anticancer therapies.	
ST	intratumor lactoferrin cancer hyperproliferative disease	
IT	Antiarteriosclerotics (antiatherosclerotics; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Neuroglia, neoplasm (astrocytoma; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Gingiva (cancer; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Uterus, neoplasm (cervix; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Intestine, neoplasm (colon; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Neoplasm (fibroma; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Neuroglia, neoplasm (glioblastoma; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Blood vessel, neoplasm (hemangioma; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Intestine, disease (inflammatory; intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases)	
IT	Adenoma	
	Antirheumatic agents	
	Antitumor agents	
	Atherosclerosis	
	Bladder, neoplasm	
	Bone, neoplasm	
	Brain, neoplasm	
	Digestive tract, neoplasm	
	Head, neoplasm	
	Human	
	Immunotherapy	
	Kidney, neoplasm	
	Leukemia	
	Lung, neoplasm	
	Lymphoma	
	Mammary gland, neoplasm	
	Osteoarthritis	
	Ovary, neoplasm	
	Pancreas, neoplasm	
	Prostate gland, neoplasm	
	Psoriasis	
	Radiotherapy	

Rheumatoid arthritis
Sarcoma
Surgery
T cell (lymphocyte)
Testis, neoplasm
Tongue, neoplasm
(intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Interleukin 18
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Lactoferrins**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Myoma
(leiomyoma; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Mouth, disease
(leukoplakia; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Adipose tissue, neoplasm
(lipoma; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Carcinoma
Mesothelium, neoplasm
(mesothelioma; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Lymphocyte
(natural killer cell; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Neoplasm
(neck; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Astrocyte
(neoplasm, astrocytoma; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Neck, anatomical
(neoplasm; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Nerve, neoplasm
(neuroblastoma; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Blood vessel, disease**
(occlusion; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Antiarthritics
(osteoarthritis; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT **Artery, disease**
(restenosis; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT Eye, neoplasm
(retinoblastoma; intratumorally administered **lactoferrin** in the treatment of malignant neoplasms and other hyperproliferative diseases)

IT 83869-56-1, Granulocyte-macrophage colony-stimulating factor
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (intratumorally administered lactoferrin in the treatment of
 malignant neoplasms and other hyperproliferative diseases)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Kruzel; US 20030096736 A1 2003 HCAPLUS
 (2) Sato; EP 0730868 A1 1996 HCAPLUS

L92 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:696760 HCAPLUS

DN 139:219356

ED Entered STN: 05 Sep 2003

TI Pharmaceutical composition for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences

IN Norrby, Klas

PA Swed.

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K038-40

ICS A61P009-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003072129	A1	20030904	WO 2003-SE329	20030227 <--
	W: AU, JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	EP 1478387	A1	20041124	EP 2003-743090	20030227 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
PRAI	SE 2002-598	A	20020227 <--		
	WO 2003-SE329	W	20030227		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003072129	ICM	A61K038-40
	ICS	A61P009-00

AB Disclosed is the use of a substance selected from the group consisting of human apolactoferrin and/or peptides derivable from human lactoferrin and/or natural metabolites of human lactoferrin and/or functionally equivalent analogs of human apolactoferrin for the production of a pharmaceutical composition for treatment and/or prevention of a vascular disease and/or states of tissue hypoperfusion with hypoxic and/or ischemic consequences. Thus, oral or s.c. administration of apolactoferrin specifically enhanced the VEGF-mediated angiogenesis.

ST apolactoferrin pharmaceutical vascular disease; tissue hypoperfusion hypoxia apolactoferrin; ischemia apolactoferrin pharmaceutical

IT Heart, disease

(angina pectoris; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT Lactoferrins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(apolactoferrins; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or

ischemic consequences)

IT **Ischemia**
(cardiac; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Necrosis**
(gangrene; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Heart, disease**
(infarction; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Drug delivery systems**
(inhalants; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Heart, disease**
(ischemia; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Ulcer**
(leg; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Drug delivery systems**
(oral; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Drug delivery systems**
(parenterals; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Ulcer**
(peptic; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Artery, disease**
(peripheral, occlusion; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Alopecia**
Angiogenesis
Blood vessel, disease
Human
Hypoxia, animal
Perfusion
(pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Lactoferrins**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Drug delivery systems**
(topical; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Digestive tract, disease**
(ulcer, peptic; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT **Leg, disease**

(ulcer; pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

IT 127464-60-2, Vascular endothelial growth factor
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (pharmaceutical compns. for treatment of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alpharma As; WO 0012541 A2 2000 HCPLUS
- (2) Anon; PATENT ABSTRACTS OF JAPAN 1996, V199(602)
- (3) Biocem Sa; JP 2001527406 TT 2001 HCPLUS
- (4) Morinaga Milk Ind Co Ltd; JP 7278011 A 1995
- (5) Morinaga Milk Industry Co Ltd; JP 09194388 A2 1997 HCPLUS
- (6) Nakajima, M; Journal of cellular physiology 1997, V170(2), PP101
- (7) Pharming B V; WO 9833509 A2 1998 HCPLUS
- (8) Science Invest Ab; WO 0001730 A1 2000 HCPLUS
- (9) Shimura, S; Investigative ophthalmology & visual science (UNITED STATES) 1998, V39(8), Pp1346

L92 ANSWER 12 OF 16 HCPLUS COPYRIGHT 2005 ACS on STN

AN 2003:551399 HCPLUS

DN 139:90498

ED Entered STN: 18 Jul 2003

TI Compositions for improving lipid metabolism

IN Harada, Etsumori; Takeuchi, Takashi; Ando, Kunio; Shimizu, Hirohiko

PA Nuclear Receptor Ligand Co., Ltd., Japan

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

IC ICM A61K038-40

ICS A61K038-16; A61K009-14; A61K009-16; A61K009-20; A61K009-48;
 A61P001-16; A61P003-04; A61P003-06; A61P003-10; A61P009-12

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057245	A1	20030717	WO 2002-JP13858	20021227 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1466621	A1	20041013	EP 2002-793463	20021227 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2005020484	A1	20050127	US 2004-500245	20040625 <--
PRAI	JP 2001-400641	A	20011228		<--
	WO 2002-JP13858	W	20021227		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003057245	ICM	A61K038-40
	ICS	A61K038-16; A61K009-14; A61K009-16; A61K009-20; A61K009-48; A61P001-16; A61P003-04; A61P003-06; A61P003-10; A61P009-12

EP 1466621 ECLA A61K038/01D; A61K038/01D6; A61K038/40 <--
 US 2005020484 ECLA A61K038/01D; A61K038/01D6; A61K038/40 <--

AB A medicinal composition contains as the active ingredient at least one member selected from the group consisting of **lactoferrin** proteins including **lactoferrin** and **conalbumin** and enzymically digested products of **lactoferrin** proteins including **lactoferricin** and peptides of **conalbumin** corresponding to **lactoferricin**. The composition is useful for improving lipid metabolism. For example, it is useful in treating lifestyle-related diseases such as **hypercholesterolemia**, **hypertriglyceridemia**, low-d. lipoprotein **hypercholesterolemia**, high-d. lipoprotein **hypocholesterolemia**, obesity, fat liver, **cholesterol** cholelithiasis, severe obesity, **hyperlipidemia**, hypertension, type II diabetes. The composition can elevate basal metabolic rate.

ST lipid metab drug disease life style habit

IT Lipids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (drugs for improving lipid metabolism)

IT Calculi, biliary
Hypercholesterolemia
Hypertension
Hypertriglyceridemia
 Obesity
 (drugs for improving lipid metabolism for treatment of)

IT Liver
 (fat; drugs for improving lipid metabolism for treatment of)

IT Lipids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hyperlipidemia; drugs for improving lipid metabolism for treatment of)

IT **Lactoferrins**
 Peptides, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in drugs for improving lipid metabolism)

IT Disease, animal
 (lifestyle-related; drugs for improving lipid metabolism for treatment of)

IT Diabetes mellitus
 (non-insulin-dependent; drugs for improving lipid metabolism for treatment of)

IT Liver
 (toxicity, fat; drugs for improving lipid metabolism for treatment of)

IT 1391-06-6, Conalbumin 146897-68-9, Lactoferricin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in drugs for improving lipid metabolism)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agennix Inc; CN 1262625 A 1998
- (2) Agennix Inc; JP 2001519815 A 1998
- (3) Agennix Inc; NZ 500712 A 1998 HCPLUS
- (4) Agennix Inc; EP 979099 A1 1998 HCPLUS
- (5) Agennix Inc; WO 9844940 A1 1998 HCPLUS
- (6) Agennix Inc; AU 9869647 A 1998 HCPLUS
- (7) Agennix Inc; MX 9909240 A1 1998 HCPLUS
- (8) Biotech Australia Pty Ltd; WO 0022909 A2 2000 HCPLUS
- (9) Biotech Australia Pty Ltd; AU 200010712 A 2000
- (10) Bukh Meditec AS; JP 05-500668 A 1991
- (11) Bukh Meditec AS; JP 2927950 B2 1991 HCPLUS
- (12) Bukh Meditec AS; EP 493513 B1 1991 HCPLUS
- (13) Bukh Meditec AS; US 5213808 A 1991 HCPLUS
- (14) Bukh Meditec AS; DE 69009769 E 1991
- (15) Bukh Meditec AS; AU 9065051 A 1991 HCPLUS
- (16) Bukh Meditec AS; WO 9104015 A1 1991 HCPLUS
- (17) Meiji Milk Products Co Ltd; JP 2000325046 A 2000 HCPLUS
- (18) Morinaga Milk Industry Co Ltd; JP 05-176713 A 1993 HCPLUS

(19) Morinaga Milk Industry Co Ltd; KR 2000070051 A 1999
 (20) Morinaga Milk Industry Co Ltd; US 6319895 B1 1999 HCPLUS
 (21) Morinaga Milk Industry Co Ltd; EP 955058 A1 1999 HCPLUS
 (22) Morinaga Milk Industry Co Ltd; WO 9830235 A1 1999 HCPLUS
 (23) Morinaga Milk Industry Co Ltd; JP 2001048808 A 2001 HCPLUS
 (24) Tokiwa Chemical Industries Ltd; JP 2000198739 A 2000 HCPLUS

IT 146897-68-9, Lactoferricin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in drugs for improving lipid metabolism)

RN 146897-68-9 HCPLUS


CN L-Phenylalanine, L-phenylalanyl-L-lysyl-L-cysteinyl-L-arginyl-L-arginyl-L-tryptophyl-L-glutaminyl-L-tryptophyl-L-arginyl-L-methionyl-L-lysyl-L-lysyl-L-leucylglycyl-L-alanyl-L-prolyl-L-seryl-L-isoleucyl-L-threonyl-L-cysteinyl-L-valyl-L-arginyl-L-arginyl-L-alanyl-, cyclic (3-20)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A



PAGE 3-A



PAGE 4-A



L92 ANSWER 13 OF 16 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:613228 HCPLUS
 ED Entered STN: 16 Aug 2002.
 TI New ingredients from dairy foods
 AU Morgan, Wendy
 CS N/A, North Sydney, NSW 2059, Australia
 SO Abstracts of Papers, 224th ACS National Meeting, Boston, MA, United States, August 18-22, 2002 (2002), AGFD-041 Publisher: American Chemical Society, Washington, D. C.
 CODEN: 69CZPZ
 DT Conference; Meeting Abstract
 LA English
 AB Dairy foods have traditionally been considered a source of nutrition, particularly high quality protein, calcium and other minerals, and vitamins. In the last few decades, milk and other dairy foods have been maligned due to their saturated fat and cholesterol contents and the belief that these constituents increase the risk of coronary heart disease. There are several studies, which indicate that dairy products may not potentiate atherosclerosis. In fact there are factors in milk that may actively protect against heart disease such as calcium, bioactive peptides, folic acid, vitamin B6, vitamin B12 and conjugated linoleic acid. A range of other activities has been demonstrated for dairy components. Milk proteins are an important source of bioactive peptides showing opioid and ACE-inhibitory activity. Lactoferrin has been shown to have a bifidus effect and antimicrobial activity. It also improves iron bioavailability. Glycomacropeptide, a-lactoglobulin, a-lactalbumin and casein phosphopeptides affect physiol. functions. The development of membrane technologies allows the fractionation of milk proteins to produce a range of products with potential impact on human health.

L92 ANSWER 14 OF 16 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:444357 HCPLUS
 DN 133:250634
 ED Entered STN: 04 Jul 2000
 TI LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells
 AU Llorente-Cortes, Vicenta; Martinez-Gonzalez, Jose; Badimon, Lina
 CS Cardiovascular Research Center, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
 SO Arteriosclerosis, Thrombosis, and Vascular Biology (2000), 20(6), 1572-1579
 CODEN: ATVBFA; ISSN: 1079-5642
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 CC 14-5 (Mammalian Pathological Biochemistry)

AB Foam cell formation is a key event in the onset and progression of atherosclerotic lesions. We have previously reported that internalization of aggregated low d. lipoproteins (agLDLs) by vascular smooth muscle cells (VSMCs) produces **cholesterol ester** (CE) accumulation in these cells. The aim of this study was to analyze whether the low d. lipoprotein receptor-related protein (LRP) mediates the uptake of agLDL by VSMCs. First, immunocytochem. and fluorescence microscopic anal. with the use of anti-LRP antibodies indicated that there was a high expression of LRP in VSMCs. Confocal microscopic anal. with the use of agLDLs labeled with fluorochrome 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine and anti-LRP antibodies showed the colocalization of agLDL and LRP. The second approach was to analyze the effect of LRP ligands on agLDL internalization; lactoferrin strongly inhibited CE accumulation from agLDLs (85.0±5.7% at 25 µg/mL) by impairing agLDL binding. Coincubation of agLDL with anti-LRP antibodies decreased in a dose-dependent manner agLDL-derived CE accumulation (from 20% at 12.5 µg/mL to 80% at 50 µg/mL). The third approach was to evaluate whether antisense LRP oligodeoxynucleotides were able to block agLDL internalization. Treatment of VSMCs with 5 µmol/L antisense LRP oligodeoxynucleotides reduced agLDL-derived CE accumulation by 84±2%. In conclusion, these results from immunol., biochem., and mol. interventions demonstrate that LRP mediates the binding and internalization of agLDL in human VSMCs. Because LRP is highly expressed in VSMCs and the uptake of 1 LDL aggregate amts. to the deposition of several hundreds of LDL particles, the uptake of agLDL through LRP could have a crucial role for lipid deposition in VSMCs.

ST LRP aggregated LDL uptake **cholesterol accumulation** vessel muscle atherosclerosis

IT Molecular association

(LDL receptor-related protein mediates binding and internalization of aggregated LDL, and **cholesterol ester** accumulation in human vascular smooth muscle cells)

IT Lipoproteins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(low-d.; LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells)

IT Blood vessel

(smooth muscle; LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells)

IT Atherosclerosis

(uptake of aggregated LDL through LDL receptor-related protein could have crucial role for lipid deposition in human vascular smooth muscle cells and onset of atherosclerotic lesions)

IT Biological transport

(uptake; LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells)

IT Receptors

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(α2-macroglobulin; LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells)

IT 57-88-5D, Cholesterol, esters

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(LDL receptor-related protein mediates binding and internalization of aggregated LDL, and **cholesterol ester** accumulation in human vascular smooth muscle cells)

(1) Asmis, R; Eur J Biochem 1995, V233, P171 HCAPLUS
(2) Aviram, M; Biochem Biophys Res Commun 1995, V216, P501 HCAPLUS
(3) Barrett, A; Biochem J 1979, V181, P401 HCAPLUS
(4) Beisiegel, U; Nature 1989, V341, P162 HCAPLUS
(5) Camejo, G; J Biol Chem 1993, V268, P14131 HCAPLUS
(6) Chappel, D; J Biol Chem 1992, V268, P14168
(7) Chappel, D; J Biol Chem 1992, V267, P25764
(8) Eisenberg, S; J Clin Invest 1992, V90, P2013 HCAPLUS
(9) Fernandez-Borja, M; J Lipid Res 1996, V37, P464 HCAPLUS
(10) Fuster, V; N Engl J Med 1992, V326, P242 MEDLINE
(11) Fuster, V; N Engl J Med 1992, V326, P310 MEDLINE
(12) Gewirtz, A; Blood 1998, V82, P712
(13) Gliemann, J; Biol Chem 1998, V379, P951 HCAPLUS
(14) Goldstein, J; Proc Natl Acad Sci USA 1979, V76, P333 HCAPLUS
(15) Gong, Q; J Biol Chem 1995, V270, P21672 HCAPLUS
(16) Guyton, J; J Lipid Res 1991, V32, P953 HCAPLUS
(17) Havel, R; J Clin Invest 1955, V34, P1345 HCAPLUS
(18) Herz, J; Curr Opin Lipidol 1993, V4, P107 HCAPLUS
(19) Herz, J; EMBO J 1988, V9, P1769
(20) Hiltunen, T; Atherosclerosis 1998, V137(suppl), PS81
(21) Hiltunen, T; Circulation 1998, V97, P1079 HCAPLUS
(22) Hoff, H; Arterioscler Thromb 1991, V11, P1209 HCAPLUS
(23) Huettinger, M; J Biol Chem 1992, V267, P18552
(24) Khoo, J; Arterioscler Thromb 1992, V12, P1258 HCAPLUS
(25) Khoo, J; Arteriosclerosis 1998, V8, P348
(26) Kowal, R; Proc Natl Acad Sci USA 1989, V86, P5810 HCAPLUS
(27) Krapp, A; J Lipid Res 1996, V37, P926 HCAPLUS
(28) Krieger, M; Annu Rev Biochem 1994, V63, P601 MEDLINE
(29) Llorente-Cortes, V; Arterioscler Thromb Vasc Biol 1998, V18, P738 HCAPLUS
(30) Llorente-Cortes, V; Atherosclerosis 1999, V144, P335 HCAPLUS
(31) Lougheed, M; J Biol Chem 1996, V271, P11798 HCAPLUS
(32) Luoma, J; J Clin Invest 1994, V93, P2014 HCAPLUS
(33) Martinez-Gonzalez, J; Eur J Clin Invest 1996, V26, P1023 MEDLINE
(34) Meilinger, M; FEBS Lett 1995, V360, P70 HCAPLUS
(35) Mikhailenko, I; J Biol Chem 1995, V270, P9593
(36) Moestrup, S; Cell Tissue Res 1992, V269, P375 HCAPLUS
(37) Moestrup, S; Exp Cell Res 1990, V190, P195 MEDLINE
(38) Moestrup, S; J Biol Chem 1990, V265, P12623 HCAPLUS
(39) Moestrup, S; J Biol Chem 1995, V266, P14011
(40) Morton, R; J Lipid Res 1986, V27, P1124 HCAPLUS
(41) Neels, J; Fibrinol Proteol 1998, V12, P219 HCAPLUS
(42) Nermine, A; Atherosclerosis 1994, V105, P79
(43) Nykjaer, A; J Biol Chem 1993, V268, P15048 HCAPLUS
(44) Pentikainen, M; J Lipid Res 1996, V37, P2638 HCAPLUS
(45) Pitas, R; J Biol Chem 1990, V265, P12722 HCAPLUS
(46) Reblin, T; J Lipid Res 1997, V38, P2103 HCAPLUS
(47) Stouffer, G; J Biol Chem 1993, V268, P18340 HCAPLUS
(48) Strickland, D; J Biol Chem 1990, V265, P17401 HCAPLUS
(49) Tabas, I; J Biol Chem 1993, V268, P20419 HCAPLUS
(50) Tertov, V; Biochem Biophys Res Commun 1989, V163, P489 HCAPLUS
(51) Tertov, V; Circ Res 1992, V71, P218 HCAPLUS
(52) Veniant, M; J Clin Invest 1998, V102, P1559 HCAPLUS
(53) Vijayagopal, P; Arterioscler Thromb Vasc Biol 1996, V16, P1112 HCAPLUS
(54) Williams, K; J Biol Chem 1992, V267, P13284 HCAPLUS
(55) Willnow, T; J Biol Chem 1992, V267, P26172 HCAPLUS
(56) Wu, S; Arch Biochem Biophys 1996, V326, P39 HCAPLUS


IT 57-88-5D, Cholesterol, esters

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(LDL receptor-related protein mediates binding and internalization of aggregated LDL, and cholesterol ester accumulation in human vascular smooth muscle cells)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L92 ANSWER 15 OF 16 HCPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:335266 HCPLUS
 DN 132:343313
 ED Entered STN: 19 May 2000
 TI Pharmaceutical preparation containing a receptor antagonist for treating blood-clotting disorders
 IN Schwarz, Hans-Peter; Turecek, Peter; Binder, Bernd
 PA Baxter Aktiengesellschaft, Austria
 SO PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 IC ICM A61K038-37
 ICS A61K038-36; A61K038-48; A61P007-04; A61K038-37; A61K038-17; A61K038-57; A61K038-49; A61K038-40; A61K038-16
 CC 1-8 (Pharmacology).

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027425	A2	20000518	WO 1999-AT271	19991110 <--
	WO 2000027425	A3	20000831		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AT 9801873	A	20011215	AT 1998-1873	19981110 <--
	AT 409335	B	20020725		
	CA 2349644	AA	20000518	CA 1999-2349644	19991110 <--
	EP 1128841	A2	20010905	EP 1999-955585	19991110 <--
	EP 1128841	B1	20040428		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002529424	T2	20020910	JP 2000-580654	19991110 <--
	AT 265225	E	20040515	AT 1999-955585	19991110 <--
	PT 1128841	T	20040930	PT 1999-955585	19991110 <--
	ES 2221457	T3	20041216	ES 1999-955585	19991110 <--
PRAI	AT 1998-1873	A	19981110 <--		
	WO 1999-AT271	W	19991110 <--		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

 WO 2000027425 ICM A61K038-37
 ICS A61K038-36; A61K038-48; A61P007-04; A61K038-37;
 A61K038-17; A61K038-57; A61K038-49; A61K038-40;
 A61K038-16
 WO 2000027425 ECLA A01K067/027A3A; A61K038/16+M; A61K038/37+M;
 A61K038/48K+M; A61K038/57+M

<--

AB A pharmaceutical preparation for treating blood-clotting disorders by increasing the biol. half-life of blood-coagulation factors contains ≥ 1 blood-coagulation factor pro-protein and a coagulation factor receptor-binding competitor (ligand) which is inert with regard to its effects on blood clotting. By preventing the internalization and degradation of the coagulation factor via the receptor, the competitor prolongs the functional half-life of the factor in vivo. The pro-protein may be Factor II, V, VII, VIII, IX, X, XI, XII, protein C, or especially von Willebrand factor. For example, the binding of activated Factor VIII to lipoprotein receptor-related protein (LRP), which is responsible for binding, internalization, and degradation of Factor VIII, is inhibited by receptor-associated protein (RAP). Thus, in mice with severe Factor VIII deficiency which were administered recombinant human Factor VIII, administration of a RAP fusion protein with glutathione S-transferase 10 min prior to Factor VIII administration greatly increased the plasma Factor VIII antigen concentration 1 h later.

ST blood coagulation factor degrdn inhibition; receptor assocd protein coagulation factor; coagulopathy treatment receptor ligand

IT **Apolipoproteins**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (E, VLDL enriched with; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Glycoproteins, specific or class**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PAAG (pregnancy-associated α 2-glycoprotein), complexes with proteinase; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Proteins, specific or class**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (RAP (receptor-associated protein); pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Blood coagulation**
 (disorder; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Toxins**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (exotoxin A, of Pseudomonas; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Ligands**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (for blood-coagulation factor receptors; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Receptors**
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(for blood-coagulation factor; pharmaceutical preparation containing receptor
antagonist for treating blood-clotting disorders)

IT **Lipoproteins**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-d.; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Proteins, specific or class**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Animal virus**
Rhinovirus
(pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Enzymes, biological studies**
Lactoferrins
Lipoproteins
Thrombospondins
Toxins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Blood-coagulation factors**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(precursors; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Lipoproteins**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(very-low-d. β -; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT **Lipoproteins**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(very-low-d., lipoprotein lipase-enriched; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

for
IT **Receptors**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(α 2-macroglobulin, ligands for; pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

IT 9001-01-8, Kallikrein 9001-24-5, Blood-coagulation factor V 9001-25-6,
Blood-coagulation factor VII 9001-26-7, Blood-coagulation factor II
9001-27-8 9001-28-9, Blood-coagulation factor IX 9001-29-0,
Blood-coagulation factor X 9001-30-3, Blood-coagulation factor XII

9001-92-7D, Proteinase, complexes with α 2-macroglobulin
 9002-04-4D, Thrombin, complexes with plasminogen activator inhibitor 1
 9004-02-8, Lipoprotein lipase 9004-06-2D, Elastase, complexes with
 antitrypsin 9013-55-2, Blood-coagulation factor XI 9039-53-6,
 Urokinase 9041-92-3D, α 1-Antitrypsin, complexes with elastase
 9087-70-1, Aprotinin 50812-37-8D, Glutathione S-transferase, fusion
 products with receptor-associated protein 60202-16-6, Blood-coagulation
 factor XIV 81604-65-1D, Heparin cofactor II, complexes with thrombin
 82657-92-9, Prourokinase 109319-16-6 139639-23-9, Tissue-type
 plasminogen activator 140208-23-7, Plasminogen activator inhibitor 1
 148196-69-4D, Protease-nexin 1, complexes with urokinase 194554-71-7,
 Proteinase inhibitor, TFPI

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical preparation containing receptor antagonist for treating blood-clotting disorders)

L92 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:708429 HCAPLUS

DN 121:308429

ED Entered STN: 24 Dec 1994

TI Modified low-density lipoprotein-(LDL) binding agents

IN Matsuda, Ichiro; Oota, Takao; Tomita, Mamoru; Shimamura, Seiichi; Kawase, Kozo; Takase, Mitsunori; Kajikawa, Mikio

PA Morinaga Milk Industry Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K037-14

ICS A61K037-18; A61M001-36

CC 63-8 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06234655	A2	19940823	JP 1993-23055	19930210 <--
	JP 3497195	B2	20040216		
PRAI	JP 1993-23055		19930210	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 06234655	ICM	A61K037-14
	ICS	A61K037-18; A61M001-36

AB Lactoferrin and/or its hydrolyzates are useful as binding agent to modified LDL for treatment of arteriosclerosis. Bovine lactoferrin was treated with acetylated human LDL to show good binding activity. Lactoferrin-containing tablets and freezed-dried preparation and immobilized lactoferrin for hemodialysis were manufactured

ST antiarteriosclerotic LDL binder lactoferrin hemodialysis

IT Antiarteriosclerotics

(lactoferrin (hydrolyzates) as binder for modified LDL for treatment of arteriosclerosis)

IT Lactoferrins

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(lactoferrin (hydrolyzates) as binder for modified LDL for treatment of arteriosclerosis)

IT Dialysis

(hemo-, lactoferrin (hydrolyzates) as binder for modified LDL for treatment of arteriosclerosis)

IT Lactoferrins

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (hydrolyzates, lactoferrin (hydrolyzates)
 as binder for modified LDL for treatment of arteriosclerosis)

IT Lipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); REM (Removal or disposal); BIOL (Biological study); PROC (Process)
 (low-d., acetylated, lactoferrin (hydrolyzates) as binder for modified LDL for treatment of arteriosclerosis)

=> => fil wpix

FILE 'WPIX' ENTERED AT 14:30:50 ON 09 MAR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 8 MAR 2005 <20050308/UP>

MOST RECENT DERWENT UPDATE: 200516 <200516/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:

[<<<](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
[<<<](http://thomsonderwent.com/coverage/latestupdates/)

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
 GUIDES, PLEASE VISIT:
[<<<](http://thomsonderwent.com/support/userguides/)

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
 FIRST VIEW - FILE WPIFV.
 FOR FURTHER DETAILS: [<<<](http://www.thomsonderwent.com/dwpifv)

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF
 HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
 Derwent Chemistry Resource display fields <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
 PLEASE CHECK:
[FOR DETAILS. <<<](http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/)

=> d all abeq tech abex tot 1116

L116 ANSWER 1 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2004-460986 [43] WPIX

DNC C2004-172138

TI Treating a cardiovascular disease comprises administering to a subject an
 effective amount of a lactoferrin composition to provide an
 improvement in the cardiovascular disease in the subject.

DC B04 D16

IN ENGELMAYER, J; GLYNN, P; VARADHACHARY, A;
 WANG, Y

PA (ENGE-I) ENGELMAYER J; (GLYN-I) GLYNN P; (VARA-I) VARADHACHARY A; (WANG-I)
 WANG Y; (AGEN-N) AGENNIX INC

CYC 107

PI WO 2004050037 A2 20040617 (200443)* EN 38 A61K000-00
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE

LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
 DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM
 PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US
 UZ VC VN YU ZA ZM ZW

US 2004152623 A1 20040805 (200452) A61K038-40 <--
 AU 2003291206 A1 20040623 (200472) A61K000-00

ADT WO 2004050037 A2 WO 2003-US38540 20031204; US 2004152623 A1
 Provisional US 2002-430867P 20021204, Provisional US 2003-498337P
 20030827, US 2003-728275 20031204; AU 2003291206 A1 AU 2003-291206
 20031204

FDT AU 2003291206 A1 Based on WO 2004050037

PRAI US 2003-498337P 20030827; US 2002-430867P
 20021204; US 2003-728275 20031204

IC ICM A61K000-00; A61K038-40

AB WO2004050037 A UPAB: 20040709

NOVELTY - Treating a cardiovascular disease comprises administering to a subject an effective amount of a **lactoferrin** composition to provide an improvement in the cardiovascular disease in the subject.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of modulating atherosclerosis in a subject comprising administering to the subject an effective amount of a **lactoferrin** composition to modulate atherosclerosis in the subject.

ACTIVITY - Cardiant; Antiarteriosclerotic. No biological data given.

MECHANISM OF ACTION - Gene therapy; HMG-coA reductase inhibitor.

USE - The method is useful for treating a cardiovascular disease, e.g. atherosclerosis (claimed).

Dwg.0/5

FS CPI

FA AB; DCN

MC CPI: B04-N02; B04-N0200E; B04-N06; B04-N0600E; B06-D01; B07-A02B; B07-A03;
 B07-D02; B07-D04C; B10-A22; B10-B01B; B10-C03; B10-C04A; B10-F02;
 B14-C03; B14-D02A2; B14-D05D; B14-F01;
 B14-F02; B14-F06; B14-F07; B14-S03;
 D05-C12; D05-H17A6

TECH UPTX: 20040709

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: In treating a cardiovascular disease, the cardiovascular disease is atherosclerosis. The **lactoferrin** composition reduces levels of circulating total cholesterol, low-density lipoproteins (LDL), very low-density lipoproteins (VLDL), or triglycerides in the subject. The **lactoferrin** composition increases the levels of circulating high-density lipoproteins (HDL) in the subject. The **lactoferrin** composition reduces the levels of vascular inflammation, circulating C-reactive protein (CRP), proliferation of vascular smooth muscle cells, vascular spasm or vascular hyper-reactivity in the subject. The **lactoferrin** composition promotes endothelial integrity or healing in the subject. The **lactoferrin** composition is dispersed in a carrier. The **lactoferrin** is mammalian **lactoferrin**. The **lactoferrin** is human or bovine. The **lactoferrin** is recombinant **lactoferrin**. The **lactoferrin** composition comprises an N-terminal **lactoferrin** variant. The N-terminal **lactoferrin** variant lacks at least the N-terminal glycine residue. The N-terminal **lactoferrin** variant comprises at least 1% to at least 50% of the **lactoferrin** composition. The **lactoferrin** composition reduces the production or activity of pro-inflammatory cytokines. The method further comprises administering a **lactoferrin** composition in combination with an anti-cholesterol agent or an anti-inflammatory agent. The anti-cholesterol agent is selected from cholesterol absorption inhibitors, bile acid sequestrants, nicotinic acid, fibrin acids and HMG-coA reductase inhibitors. The bile acid sequestrants are selected from cholestyramine, colestipol and

colesevalam. The fibric acids are selected from gemfibrozil, fenofibrate and clofibrate. The HMG-coA reductase inhibitors are selected from lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin and cerivastatin. In modulating atherosclerosis in a subject, the modulating is reducing the incidence or severity of atherosclerosis in the subject.

ABEX UPTX: 20040709

ADMINISTRATION - Dosage is 1 ng-20 g per day or 0.1-5 g per day. The **lactoferrin** composition is administered parenterally, e.g. subcutaneously, intramuscularly, intraperitoneally, intravenously, intraarterially, intramyocardially, transendocardially, transepically, or intrathecally, or orally (all claimed).

L116 ANSWER 2 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-247885 [23] WPIX

DNC C2004-096768

TI New peptidyl analogs are growth hormone secretagogue agonists useful in the treatment of e.g. weight loss, sexual dysfunction, diabetes or cardiovascular diseases.

DC B04 C03

IN ZHENG, X D

PA (SCRC) SCRAS SOC CONSEILS RECH & APPL SCI

CYC 105

PI WO 2004014415 A1 20040219 (200423)* EN 77 A61K038-40 <--
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH
 PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC
 VN YU ZA ZM ZW

AU 2003259062 A1 20040225 (200456) A61K038-40 <--

ADT WO 2004014415 A1 WO 2003-US24834 20030808; AU 2003259062 A1 AU 2003-259062
 20030808

FDT AU 2003259062 A1 Based on WO 2004014415

PRAI US 2002-402263P 20020809

IC ICM A61K038-40

AB WO2004014415 A UPAB: 20040405

NOVELTY - Peptidyl analogs (I) or their salts are new.

DETAILED DESCRIPTION - Peptidyl analogs of formula R1- A1- A2- A3- A4- A5-R2 (I) or their salts are new.

A1 = Aib, amino piperidinylcarboxylic acid (Apc) or isonipecotic acid (Inp);

A2 and A3 = S1, beta -(1-naphthyl)-D-alanine (D-1Nal), beta -(2-naphthyl)-D-alanine (D-2Nal), D-Ser(Bzl) or D-Trp;

S1 = 3-benzoylthienyl-D-alanine (D-Bal), 4,4'-biphenyl-D-alanine (D-Bip), 4-benzoyl-D-phenylalanine (D-Bpa) or beta , beta -diphenyl-D-alanine (D-Dip);

A4 = S2, S4, Phe or 2'- (4-phenyl)imidazolyl (Pim);

S2 = beta -(2-furyl)-alanine (2Fua), pentafluorophenylalanine (Pff), beta -(4-thiazolyl)alanine (Taz), or Thr(Bzl);

S4 = beta -(2-thienyl)alanine (2Thi), beta -(3-thienyl)alanine (3Thi), Orn, beta -(2-pyridyl)alanine (2Pal), beta -(3-pyridyl)alanine (3Pal) or beta -(4-pyridyl)alanine (4Pal);

A5 = Apc, S3 or none;

S3 = 2,4-diaminobutyric acid (Dab), 2,3-diaminopropionic acid (Dap), Lys or Orn;

R1 = H, 1-6C alkyl, 5-14C aryl, 1-6C alkyl-5-14C aryl, 3-8C cycloalkyl or 2-10C acyl; and

R2 = OH, NH2.

Provided that:

(a) when A5 is S3, then A2 or A3 is S1 or A4 is S2; and
 (b) when A5 is absent then A3 is D-Bip, D-Bpa or D-Dip or A4 is S2 or
 A1 is Apc and A2 or A3 is S1 or A4 is S4.

ACTIVITY - Antidiabetic; Anorectic; Cardiovascular-Gen.; Cardiant; Osteopathic; Endocrine-Gen.; Cytostatic; Immunomodulator; Muscular-Gen.; Ophthalmological.

MECHANISM OF ACTION - Growth hormone secretagogue (GHS) agonist; Ghrelin agonist; Ghrelin antagonist; Growth hormone secretion stimulator; Growth hormone secretion antagonist.

Test details are described but no results are given.

USE - Used:

(1) in the treatment of a growth hormone deficient state, for facilitating weight gain, maintenance of weight and/or appetite increase in a disease or disorder accompanied by weight loss (including anorexia, bulimia, cancer cachexia, AIDS, AIDS wasting, cachexia, wasting in frail elderly, chemotherapy, radiation therapy, immobilization or dialysis);

(2) for increasing muscle mass and bone density, sexual dysfunction, maintenance of weight for physical functioning, recovery of physical function;

(3) for facilitating weight loss and treating obesity due to a disease or condition (including hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis or cancers);

(4) for appetite decrease, weight maintenance;

(5) for diabetes, complications of diabetes including retinopathy, cardiovascular disorders;

(6) for achieving a beneficial cardiovascular effect (e.g. inhibition of apoptosis of cardiomyocytes, cardiac endothelial cells or vascular endothelial cells, attenuation of the development of cardiac cachexia, reduction in systemic vascular resistance, an increase in cardiac output or improvement of cardiac structure or function) in human;

(7) for chronic/severe heart failure and for eliciting ghrelin agonist/antagonist effect (claimed).

Also useful for facilitating weight gain in farm animals (e.g. pigs, cows or chickens).

ADVANTAGE - The compounds are potent growth hormone secretagogues.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B04-C01A; B14-D01; B14-E11; B14-E12; **B14-F01**;
B14-F02; B14-L01; B14-L06; B14-N01; B14-P02; B14-S04;
 C04-C01A; C14-D01; C14-E11; C14-E12; **C14-F01**;
C14-F02; C14-L01; C14-L06; C14-N01; C14-P02; C14-S04

TECH UPTX: 20040405

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: (I) Is prepared by using standard solid phase peptide synthesis reported in Stewart, J.M. et al., Solid Phase Synthesis (Pierce Chemical Co., 2nd ed. 1984).

ABEX UPTX: 20040405

SPECIFIC COMPOUNDS - 180 Compounds are specifically claimed as (I), e.g. Inp-D-1Nal-D-Trp-3Pal-Lys-NH₂ (Ia).

ADMINISTRATION - Dosage of (I) is 0.01-1000 mg/day and is administered orally, nasally, transdermally, transmucosally, intravenously, intraperitoneally, subcutaneously, topically or intramuscularly.

EXAMPLE - 3-Benzothienylalanine (D-Bal) -D-Trp-Phe-amino piperidinylcarboxylic acid (Apc) -Rink amide resin was treated with Fmoc-isonipecotic acid (Inp) (0.27 mmol) using N,N-diisopropylcarbodiimide (0.27 mmol) in 1-hydroxy-benzotriazole (HOBT) and dimethylformamide (DMF). The resulting product was treated with piperidine (20 %) in DMF. The peptide was treated with triisopropylsilane (8 %) in trifluoroacetic acid (1.5 ml) at room temperature for 2 hours to yield Inp-D-Bal-D-Trp-Phe-Apc-NH₂.

DEFINITIONS - Preferred Definitions:

A1 = Apc or Inp;

A2 = S5 or D-Bip;

S5 = D-Bal, D-1Nal or D-2Nal;
 A3 = S5 or D-Trp; and
 A4 = 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi or Thr(Bzl).

L116 ANSWER 3 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2004-035048 [03] WPIX
 CR 2004-071004 [07]
 DNC C2004-011624
 TI Treating a hyperproliferative disease (e.g. cancer, psoriasis, adenoma or atherosclerosis) in a subject comprises administering a composition of a human lactoferrin alone or in combination with standard anti-cancer therapies.
 DC B04
 IN BARSKY, R; PERICLE, F; PETRAK, K; VARADHACHARY, A; WANG, Y; O'MALLEY, B
 PA (BARS-I) BARSKY R; (PERI-I) PERICLE F; (PETR-I) PETRAK K; (VARA-I) VARADHACHARY A; (WANG-I) WANG Y; (OMAL-I) O'MALLEY B; (AGEN-N) AGENNIX INC
 CYC 104
 PI WO 2003099323 A1 20031204 (200403)* EN 51 A61K038-40 <--
 RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
 LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL
 PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU
 ZA ZM ZW
 US 2004009895 A1 20040115 (200406) A61K038-40 <--
 US 2004082504 A1 20040429 (200429) A61K038-40 <--
 AU 2003273182 A1 20031212 (200443) A61K038-40 <--
 EP 1507554 A1 20050223 (200515) EN A61K038-40 <--
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR
 ADT WO 2003099323 A1 WO 2003-US14789 20030509; US 2004009895 A1
 Provisional US 2002-379441P 20020510, Provisional US
 2002-379442P 20020510, Provisional US 2002-379474P 20020510
 , US 2003-434769 20030509; US 2004082504 A1 Provisional US
 2002-379441P 20020510, Provisional US 2002-379442P 20020510
 , Provisional US 2002-379474P 20020510, US 2003-435319 20030509;
 AU 2003273182 A1 AU 2003-273182 20030509; EP 1507554 A1 EP 2003-755357
 20030509, WO 2003-US14789 20030509
 FDT AU 2003273182 A1 Based on WO 2003099323; EP 1507554 A1 Based on WO
 2003099323
 PRAI US 2002-379474P 20020510; US 2002-379441P
 20020510; US 2002-379442P 20020510; US
 2003-434769 20030509; US 2003-435319 20030509
 IC ICM A61K038-40
 ICS A23L001-305
 AB WO2003099323 A UPAB: 20050303
 NOVELTY - Treating a hyperproliferative disease comprises administering orally, intravenously or topically to a subject a human lactoferrin composition in an amount sufficient to provide an improvement in the hyperproliferative disease in the subject.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
 (1) a method of enhancing a mucosal immune response in the gastrointestinal tract in a subject, comprising administering orally to the subject a human lactoferrin;
 (2) a method of reducing growth of a neoplasm in a subject, comprising administering orally to the subject a human lactoferrin composition in an amount to reduce the growth of the neoplasm in the subject;
 (3) methods of enhancing a systemic or local immune response

following the step of administering intravenously or topically to the subject a **lactoferrin** composition; and

(4) methods of stimulating interleukin-18 or GM-CSF in a subject, comprising administering to the subject the **lactoferrin** composition.

ACTIVITY - Cytostatic; Antirheumatic; Antiarthritic; Antiinflammatory; Osteopathic; Vasotropic; Antiarteriosclerotic; Antipsoriatic. No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The methods are useful in treating malignant neoplasms (e.g. melanoma or leukemia) and other hyperproliferative diseases such as rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia or psoriasis.

Dwg.0/5

FS CPI

FA AB; DCN

MC CPI: B04-N02; B14-C09A; B14-C09B; B14-E10C; **B14-F01G**;
B14-F07; B14-H01; B14-H01A; B14-H01B; B14-N17C

TECH UPTX: 20040112

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: In treating a hyperproliferative disease, the human **lactoferrin** composition is dispersed in a pharmaceutical carrier. The human **lactoferrin** is a recombinant human **lactoferrin**. The method further comprises administering an antacid in conjunction with the human **lactoferrin** composition. The hyperproliferative disease is cancer, which comprises a neoplasm. The neoplasm is selected from melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, glioblastoma, leukemia, neuroblastoma, squamous cell, head, neck, gum, tongue, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, sarcoma, cervical, gastrointestinal, lymphoma, brain, colon, and bladder neoplasm. The neoplasm is a hematopoietic neoplasm selected from acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, multiple myeloma and chronic lymphocytic leukemia. The hyperproliferative disease is selected from rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, and psoriasis. Alternatively, the method comprises supplementing the mucosal, local or systemic immune system in a subject by increasing the amount of human **lactoferrin** in the gastrointestinal tract, in the vicinity of a tumor, or in the systemic circulation, respectively. The human **lactoferrin** stimulates the production of interleukin-18 or GM-CSF. Treating a hyperproliferative disease alternatively comprises administering to the subject the human **lactoferrin** composition in combination with chemotherapy, biotherapy, immunotherapy, surgery or radiotherapy. The **lactoferrin** may also be a bovine **lactoferrin**. The composition is a topical gel, a solution, capsule or a tablet having a **lactoferrin** concentration of about 0.01-20 (preferably 1.0-8.5)%. In enhancing a mucosal immune response in the gastrointestinal tract in a subject, the **lactoferrin** stimulates interleukin-18 or GM-CSF in the gastrointestinal tract. The interleukin-18 stimulates the production, maturation or activity of immune cells, such as T-lymphocytes or natural killer cells. The T-lymphocytes are selected from CD4+, CD8+ and CD3+ cells. The GM-CSF stimulates the production, maturation or activity of immune cells such as dendritic or other antigen presenting cells. The subject suffers from a hyperproliferative disease. The method further comprises additionally administering radiotherapy. Enhancing the mucosal or systemic immune response in the subject further comprises administering chemotherapy, immunotherapy, surgery, biotherapy, radiotherapy or their

combinations. The chemotherapy is a platinum-based agent (i.e. cisplatin) or a taxane-based agent (i.e. docetaxel). Reducing growth of a neoplasm in a subject further comprises administering the above-mentioned chemotherapy, immunotherapy, surgery, biotherapy, radiotherapy or their combinations. It further comprises administering radiotherapy.

ABEX UPTX: 20040112

ADMINISTRATION - The amount of the composition that is administered orally is about 1 mg to about 100 g per day, preferably about 20 mg to about 10 g per day (claimed). When administered intravenously or topically, the amount of the composition is about 0.1 microg to about 10 g per day, preferably about 1 mug to 1 g per day (claimed). The composition may also be administered by intratumoral, nasal, buccal, rectal, vaginal, intramuscular, intraperitoneal, intraarterial or dermal means.

L116 ANSWER 4 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2003-712670 [67] WPIX
 DNC C2003-196034
 TI Use of human apo-lactoferrin and peptides derivable from human lactoferrin for the production of composition useful for e.g. treating and preventing vascular disease.
 DC B04
 IN NORRBY, K
 PA (NORR-I) NORRBY K
 CYC 29
 PI WO 2003072129 A1 20030904 (200367)* EN 14 A61K038-40 <--
 RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE
 SI SK TR
 W: AU JP US
 AU 2003210086 A1 20030909 (200428) A61K038-40 <--
 EP 1478387 A1 20041124 (200477) EN A61K038-40 <--
 R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT
 SE SI SK TR
 ADT WO 2003072129 A1 WO 2003-SE329 20030227; AU 2003210086 A1 AU 2003-210086
 20030227; EP 1478387 A1 EP 2003-743090 20030227, WO 2003-SE329 20030227
 FDT AU 2003210086 A1 Based on WO 2003072129; EP 1478387 A1 Based on WO
 2003072129
 PRAI SE 2002-598 20020227
 IC ICM A61K038-40
 ICS A61P009-00
 AB WO2003072129 A UPAB: 20031017
 NOVELTY - In the production of a composition, a substance containing human apo-lactoferrin and/or peptides derivable from human lactoferrin and/or its natural metabolites or equivalent analogs is used.

ACTIVITY - Antianginal; Cerebroprotective; Cardiant; Antiulcer; Antialopecia.

MECHANISM OF ACTION - VEGF165 induced angiogenesis inhibitor.

Lactoferrin, dissolved in saline, was given by tube feeding twice daily from Sunday afternoon (Day-1) to Friday afternoon (Day 4). Vehicle controls received saline by tube feeding. The angiogenesis treatment with VEGF was given intraperitoneally on Days 0 - 4 (twice daily). The results for test/control groups were vascularized area = 12.09 plus or minus 1.49/1.18 plus or minus 0.5, microvascular length = 1.465 plus or minus 0.077/0.28 plus or minus 0.04, and total microvascular length = 17.72 plus or minus 2.19/0.33 plus or minus 0.14 respectively. The results demonstrated that oral administration of apo-hLE significantly enhanced the VEGF mediated angiogenic response.

USE - For treating and/or preventing vascular disease and/or states of tissue hypoperfusion (including impending or manifested stroke, ischemic heart disease e.g. angina pectoris or impending or manifested myocardial infarction), or peripheral artery occlusive disease with or without impending gangrene and/or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or

generalized hair loss) with hypoxia and/or ischemic consequences (claimed).

ADVANTAGE - The method is used in as an alternative to bypass surgery or any therapeutic angiogenesis options.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B04-C01; B04-N02; B04-N02B; B14-E08; B14-F01;
B14-F01D; B14-F02; B14-F02D;
B14-F02D1; B14-F02F; B14-K01; B14-N16; B14-R02

TECH UPTX: 20031017

TECHNOLOGY FOCUS - BIOLOGY - Preferred Substance: The substance is human **apolactoferrin**, human **lactoferricin**, a peptide constituted of 12 - 40 amino acids of human **lactoferrin** counted from the N-terminal end or its modified version, a peptide formed of a sequences constituted of 16 - 40 amino acids and 18 - 40 amino acids from the N-terminal and of human **lactoferrin** or its modified version, a peptide corresponding to 18 - 31 residues of human **lactoferrin** (where C-20 is replaced by A, Q-22 is replaced by K and N-26 is replaced by D), a peptide formed of the amino acids in positions 12 - 31, counted from the N-terminal end, in the sequence constituting human **lactoferrin**, or its modification or its fragment consisting of at least 7 amino acids, a peptide consisting of 11 - 17 amino acids corresponding to the sequences that begin with one of the amino acids in positions 15 - 21 and end with the amino acid in position 31, counted from the N-terminal and, in the sequence constituting human **lactoferrin** or its modification, or a peptide consisting of 12 amino acids based on the sequence consisting of the amino acids in positions 20 - 31 in human **lactoferrin**, counted from the N-terminal end.

ABEX UPTX: 20031017

ADMINISTRATION - The route of administration is oral, parenteral, local or by inhalation. No dosage given.

EXAMPLE - No relevant example given.

L116 ANSWER 5 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2003-598327 [56] WPIX

DNC C2003-162395

TI Composition for e.g. improving lipid metabolism useful in treating lifestyle-related diseases like hypercholesterolemia and (severe) obesity comprises **lactoferrin** proteins and their enzymatic digestion products,.

DC B04

IN ANDO, K; HARADA, E; SHIMIZU, H; TAKEUCHI, T

PA (NUCL-N) NUCLEAR RECEPTOR LIGAND CO LTD; (NRLP-N) NRL PHARMA INC; (ANDO-I) ANDO K; (HARA-I) HARADA E; (SHIM-I) SHIMIZU H; (TAKE-I) TAKEUCHI T

CYC 103

PI WO 2003057245 A1 20030717 (200356)* JA 51 A61K038-40 <--
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU
MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
ZM ZW

AU 2002359949 A1 20030724 (200421) A61K038-40 <--

EP 1466621 A1 20041013 (200467) EN A61K038-40 <--

R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC
MK NL PT RO SE SI SK TR

US 2005020484 A1 20050127 (200509) A61K038-40 <--

ADT WO 2003057245 A1 WO 2002-JP13858 20021227; AU 2002359949 A1

AU 2002-359949 20021227; EP 1466621 A1 EP 2002-793463

20021227, WO 2002-JP13858 20021227; US 2005020484 A1

WO 2002-JP13858 20021227, US 2004-500245 20040625

FDT AU 2002359949 A1 Based on WO 2003057245; EP 1466621 A1 Based on WO 2003057245

PRAI JP 2001-400641 20011228

IC ICM A61K038-40

ICS A61K009-14; A61K009-144; A61K009-16; A61K009-166; A61K009-20; A61K009-200; A61K009-48; A61K009-488; A61K038-16; A61K038-166; A61P001-16; A61P001-166; A61P003-04; A61P003-044; A61P003-06 ; A61P003-066; A61P003-10; A61P003-100; A61P009-12; A61P009-122

AB WO2003057245 A UPAB: 20030903

NOVELTY - Composition comprises one or more of **lactoferrin** proteins (I) including **lactoferrin** and conalbumin, and their enzymatic digestion products such as **lactoferrin** and peptides of conalbumin corresponding to **lactoferrin**.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the preparation of the composition comprising mixing (I) with pharmaceutically-acceptable additives in dry state for pressing into grains for filling capsules, or for producing powders, granules or tablets;

ACTIVITY - Antilipemic; Anorectic; Antidiabetic; Hepatotropic.

Test details are described, but no results are given.

MECHANISM OF ACTION - None given in source material.

USE - The compositions are used for improving lipid metabolism and elevating basal metabolic rate, which is useful in treating lifestyle-related diseases such as hypercholesterolemia, hypertriglyceridemia, low-density lipoprotein hypercholesterolemia, high-density lipoprotein hypcholesterolemia, obesity, fatty liver, cholesterol cholelithiasis (all claimed), hyperlipemia and type II diabetes.

Dwg.0/14

FS CPI

FA AB; DCN

MC CPI: B04-N06; B14-D02A2; B14-E12; B14-F06; B14-N12; B14-S04

ABEX UPTX: 20030903

ADMINISTRATION - Administration is oral, e.g. in the form of powders, granules, tablets, capsules, enteric preparations particularly with coating resistant to gastric juice but soluble in the small intestine or as drinks. The dosage is 0.1-50000 (preferably 10-2000) mg daily.

EXAMPLE - A composition was formulated from **lactoferrin** (1 part) and potato starch (1 part) with water to produce grains, which were then filled into capsules at 150 mg each.

L116 ANSWER 6 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1994-307580 [38] WPIX

DNN N1994-242039 DNC C1994-140034

TI Denatured low density lipoprotein-combining agent - comprises **lactoferrin** and/or hydrolysate shows antimicrobial activity and is used in treatment of progressive arteriosclerosis.

DC B04 P34

PA (MORG) MORINAGA MILK IND CO LTD

CYC 1

PI JP 06234655 A 19940823 (199438)* 8 A61K037-14 <--
JP 3497195 B2 20040216 (200413) 8 A61K038-16

ADT JP 06234655 A JP 1993-23055 19930210; JP 3497195 B2 JP 1993-23055 19930210

FDT JP 3497195 B2 Previous Publ. JP 06234655

PRAI JP 1993-23055 19930210

IC ICM A61K037-14; A61K038-16

ICS A61K037-18; A61K038-00; A61M001-36; A61P009-10

AB JP 06234655 A UPAB: 19941115

Denatured low density lipoprotein-combining agent comprises (a)

lactoferrin and/or (b) hydrolysate.

USE/ADVANTAGE - **Lactoferrin** is iron-combining protein derived from milk, tear, saliva, blood etc. and is known to show antimicrobial activity and to involve in inflammation. It was found to specifically combine with denatured LDL e.g. LDL oxidised with free radical, selectively remove the LDL, and inhibit incorporation of the LDL into macrophage so that foaming of macrophage is inhibited. This agent is therefore useful for prevention and treatment of progressive arteriosclerosis.

Dwg.0/6

FS CPI GMPI

FA AB; GI

MC CPI: B04-N02; B14-F07

L116 ANSWER 7 OF 7 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1994-238662 [29] WPIX

DNC C1994-108974

TI Brain protectant for preventing ischaemic diseases without side effects - comprising 31 specified peptide(s), prepared by **lactoferrin** hydrolysis.

DC B04

PA (MORG) MORINAGA MILK IND CO LTD

CYC 1

PI JP 06172200 A 19940621 (199429)* 11 A61K037-02 <--

ADT JP 06172200 A JP 1992-327738 19921208

PRAI JP 1992-327738 19921208

IC ICM A61K037-02

ICA A61K037-14; A61K037-18; C07K005-08; C07K005-10; C07K007-06; C07K007-08; C07K007-10

ICI C07K099:

AB JP 06172200 A UPAB: 19940907

Compsn. comprises 31 specified peptides, their derivs. or salts, or their mixts..

Lactoferrin is pref. chemically or enzymically hydrolysed to give 31 peptides having 3-47 amino acid sequences with brain protecting property. The peptides also have antimicrobial activity and their pharmaceutical prepsn. may be prepared without addition of antiseptics. The peptides are administered at least at doses of 10 mg for parenteral and 100mg for oral admin..

USE/ADVANTAGE - Stable, heat resistant, water soluble and antimicrobial brain protectant is used for the prevention of ischaemic diseases without side effects.

In an example, a peptide having 25 amino acids, Phe-Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met -Lys-Lys-Leu-Gly-Ala-Pro-Ser -Ile-Thr-Cys-Val-Arg-Arg-Ala-Phe, exhibited brain protecting effect in decapitated male ddy mice at doses of at 10 mg/kg by intraperitoneal, and 50 mg/kg by subcutaneous admin. respectively.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B04-C01; B04-N02A; B14-A01; B14-F02D1

=> d his

(FILE 'HOME' ENTERED AT 12:52:20 ON 09 MAR 2005)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:52:25 ON 09 MAR 2005

E LACTOFERRIN

L1 224 S E3,E4,E8

L2 23 S E1,E2,E5-E7 NOT L1

FILE 'HCAPLUS' ENTERED AT 12:53:57 ON 09 MAR 2005

E LACTOFERRIN/CT
 L3 3804 S E6-E10
 E E6+ALL
 L4 3828 S E4,E3
 L5 4954 S LACTOFERRIN OR LACTOTRANSFERRIN
 L6 349 S L1 OR L2
 L7 5056 S L3-L6
 L8 1 S LACTO() (FERRIN OR TRANSFERRIN OR TRANS FERRIN)
 L9 5056 S L7,L8
 E ATHEROSCLEROSIS/CT
 L10 26376 S E3,E4
 E E3+ALL
 L11 5033 S E10-E13
 L12 45035 S E9,E11,E12,E13/BI
 E E8+ALL
 L13 8095 S E8
 L14 10796 S E8/BI
 E E15+ALL
 L15 8237 S E4
 L16 32 S L9 AND L10-L15
 E CARDIOVASCULAR/CT
 E E5+ALL
 L17 63843 S E3+NT
 E E19+ALL
 L18 245711 S E4,E3+NT
 E E250+ALL
 L19 375833 S E3+NT
 E HEART DISEASE/CT
 E E4+ALL
 E E2+ALL
 L20 82991 S E8,E9,E7+NT
 E E92+ALL
 L21 216429 S E5,E4+NT
 L22 6523 S E10+OLD,NT
 L23 189 S L9 AND L17-L22
 L24 12 S L9 AND CARDIOVASCULAR(L) (DISEASE OR DISORDER OR DYSFUNCTION?)
 L25 194 S L16,L23,L24

FILE 'REGISTRY' ENTERED AT 12:59:21 ON 09 MAR 2005

L26 1 S CHOLESTEROL/CN
 E C-REACTIVE PROTEIN/CN
 L27 1 S E3
 L28 106 S C REACTIVE PROTEIN

FILE 'HCAPLUS' ENTERED AT 13:00:01 ON 09 MAR 2005

L29 107734 S L26 OR L27 OR L28
 L30 60 S L29 AND L9
 L31 137 S (?CHOLESTER? OR CRP OR C REACTIVE(L) PROTEIN) AND L9
 L32 30 S TRIGLYCER? AND L9
 L33 33 S ?VASCUL?(L)?INFLAM? AND L9
 L34 1 S ?VASCUL?(L)?SPASM? AND L9
 L35 1 S BLOOD VESSEL+OLD,NT/CT (L) SPASM? AND L9
 L36 1 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) SPASM? AND L9
 L37 34 S PROTEIN?/CW,CT (L) C REACTIVE AND L9
 L38 1 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) HYPERREACT? AND L9
 L39 1 S BLOOD VESSEL+OLD,NT/CT (L) HYPERREACT? AND L9
 L40 6 S BLOOD VESSEL+OLD,NT/CT (L) SMOOTH MUSCL? AND L9
 L41 4 S BLOOD VESSEL, DISEASE+OLD,NT/CT (L) SMOOTH MUSCL? AND L9
 L42 6 S INFLAMM?/CW,CT (L) VASCUL? AND L9
 L43 0 S INFLAMM?/CW,CT (L) PRO(L) CYTOKIN? AND L9
 L44 10 S INFLAMM?/CW,CT (L) CYTOKIN? AND L9
 L45 37 S CYTOKINE?/CW,CT (L) ?INFLAM? AND L9

E CYTOKINE/CT
 L46 72 S E77+OLD, NT (L) ?INFLAM? AND L9
 L47 14 S BLOOD VESSEL, DISEASE+OLD, NT/CT (L) ENDOTHEL? AND L9
 L48 39 S BLOOD VESSEL+OLD, NT/CT (L) ENDOTHEL? AND L9
 L49 12 S ENDOTHELIUM+OLD, NT/CT (L) VASCUL? AND L9
 E HYPERCHOLESTEROL/CT
 L50 7 S E5, E6 AND L9
 E E5+ALL
 L51 0 S E5 AND L9
 E HYPERTRIGLYCER/CT
 E E4+ALL
 L52 4 S E4, E5 AND L9
 E LOW DENSITY LIPOPROTEIN/CT
 E L DENSITY LIPOPROTEIN/CT
 E LIPOPROTEIN/CT
 L53 12 S E100-E109, E113, E114 AND L9
 L54 54 S E135-E146 AND L9
 E E51+ALL
 L55 56 S E2+NT (L) (LOW OR VERY LOW) () (DENSITY OR D OR DEN) AND L9
 L56 12 S E2+NT (L) HIGH() (DENSITY OR D OR DEN) AND L9
 L57 19 S E2+NT (L) (LDL OR VLDL OR HDL OR VHDL) AND L9
 L58 401 S L30-L57, L25
 L59 1 S US20040152623/PN OR WO2003-US38540/AP, PRN
 E VARADHACHARY A/AU
 L60 19 S E3, E7
 E GLYNN P/AU
 L61 53 S E3-E9, E17-E19
 E WANG Y/AU
 L62 2479 S E3, E40-E43
 E WANG YEN/AU
 L63 11 S E3, E34
 L64 13 S E50
 E ENGELMAYER J/AU
 L65 9 S E4
 E AGENNIX/AP, CS
 E AGENNIX/PA, CS
 E AGENIX/PA, CS
 L66 17 S E3-E21
 L67 10 S L59-L66 AND L58
 L68 10 S L67 AND L3-L25, L29-L67
 L69 341 S L58 AND (PD<=20021204 OR PRD<=20021204 OR AD<=20021204)
 L70 106 S L69 AND (PHARMACEUT? OR PHARMACOL?)/SC, SX
 E DRUG DELIVERY/CT
 L71 2 S E27-E31, E39 AND L70
 L72 0 S E53, E55, E58, E64, E70, E71 AND L70
 L73 0 S E89, E107 AND L70
 L74 50 S E6-E217 AND L70
 E E6+ALL
 L75 6 S E3-E5 AND L70
 L76 53 S E2+NT AND L70
 L77 53 S L71, L74-L76
 L78 106 S L70, L77

FILE 'REGISTRY' ENTERED AT 13:36:48 ON 09 MAR 2005

FILE 'REGISTRY' ENTERED AT 13:37:26 ON 09 MAR 2005

L79 14 S 59-67-6 OR 943-45-3 OR 11041-12-6 OR 50925-79-6 OR 182815-43-
 L80 717 S (59-67-6 OR 943-45-3 OR 11041-12-6 OR 50925-79-6 OR 182815-43
 L81 1 S 9028-35-7

FILE 'HCAPLUS' ENTERED AT 13:38:11 ON 09 MAR 2005

L82 6 S L79, L80, L81 AND L78
 L83 8 S L79, L80, L81 AND L69

L84 1 S BILE ACID (L) SEQUESTR? AND L69,L78
 L85 7 S L82-L84,L78 AND ?ATHEROSCLERO?
 L86 23 S L69 AND ?ATHEROSCLERO?
 L87 23 S L85,L86
 SEL DN AN 1 7 12
 L88 3 S L87 AND E1-E7
 L89 99 S L78 NOT L87
 SEL DN AN 8 19 21 68 89
 DEL SEL
 SEL DN AN 8 19 21 68 96
 L90 5 S L89 AND E1-E15
 L91 16 S L88,L90,L68
 L92 16 S L91 AND L3-L25,L29-L78,L82-L91

FILE 'HCAPLUS' ENTERED AT 13:53:44 ON 09 MAR 2005

FILE 'WPIX' ENTERED AT 13:55:12 ON 09 MAR 2005

L93 1 S L59
 L94 161 S A61K038-40/IPC
 L95 693 S L5/BIX OR L8/BIX
 L96 683 S ?LACTOFERRIN?/BIX
 L97 752 S L94-L96
 L98 4 S L97 AND (B14-D02A2 OR C14-D02A2 OR B12-H03 OR C12-H03)/MC
 L99 80 S L97 AND (B14-F? OR C14-F? OR B12-F? OR C12-F?)/MC
 L100 9 S L97 AND A61P009/IPC
 L101 2 S L97 AND A61P003-06/IPC
 L102 55 S L97 AND (P5? OR P814)/M0,M1,M2,M3,M4,M5,M6
 L103 97 S L98-L102
 L104 90 S L103 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
 L105 20 S L104 AND N135/M0,M1,M2,M3,M4,M5,M6
 L106 33 S L104 AND D05-H?/MC
 L107 35 S L105,L106
 SEL DN AN 2
 L108 1 S L107 AND E16-E17
 L109 55 S L104 NOT L107
 SEL DN AN 10 15 21 23 52 54
 L110 6 S L109 AND E18-E30
 L111 7 S L93,L108,L110
 L112 13 S L97 AND (ENGELMAYER ? OR GLYNN ? OR VARADHACHARY ? OR WANG ?)
 L113 16 S L97 AND AGEN?/PA
 L114 19 S L112,L113
 L115 2 S L111 AND L114
 L116 7 S L111,L115
 L117 17 S L114 NOT L116

FILE 'WPIX' ENTERED AT 14:30:50 ON 09 MAR 2005

=>